[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f-uXVTsdJ4LRmWbguGpcJA9CCpAgv4TNoTzJkc5J9Rtg":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":84,"rows":91},"H. Lundbeck A\u002FS",[4],222,false,14,82,58258,8,2,[14,17,20,23,26,29,31,34],{"name":15,"count":16},"Healthy",34,{"name":18,"count":19},"Major Depressive Disorder",29,{"name":21,"count":22},"Schizophrenia",28,{"name":24,"count":25},"Migraine",15,{"name":27,"count":28},"Alzheimer's Disease",10,{"name":30,"count":28},"Primary Insomnia",{"name":32,"count":33},"Healthy Participants",9,{"name":35,"count":11},"Parkinson Disease",[37,42,47,52,57,61,66,70,75,80],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT05104476","A Study of Lu AF82422 in Participants With Multiple System Atrophy","2023-11-16","Lu AF82422",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT06323928","A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments","2026-01-16","Lu AG09222",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT06557850","A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease","2026-03-17","Lu AG22515",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT06701526","A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications","2026-06-05","Eptinezumab",{"nctId":58,"briefTitle":59,"date":60,"intervention":56},"NCT04965675","A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine","2026-09-05",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT06471829","A Trial of Lu AG13909 in Adult Participants With Cushing's Disease","2026-09-15","Lu AG13909",{"nctId":67,"briefTitle":68,"date":69,"intervention":65},"NCT05669950","A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia","2026-09-30",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT07613710","A Trial to Test the Safety and Tolerability of Lu AH69593 in Adults That Are Healthy or Have Narcolepsy","2026-12-01","Lu AH69593",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT07513441","A Trial of Lu AF28996 in Participants With Parkinson's Disease (PD)","2027-05-31","Lu AF28996",{"nctId":81,"briefTitle":82,"date":83,"intervention":56},"NCT05897320","A Study of Eptinezumab in Pediatric Participants With Episodic Migraine","2027-07-06",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,267,293,374,403,473,512,542,564,640,710,771,821,860,884,909,927,945,963,981,1006,1129,1210,1299,1344,1392,1429,1477,1505,1536,1567,1610,1648,1670,1701,1733,1763,1795,1826,1853,1884,1913,1931,1954,1972,1994,2012,2036,2054,2072,2090,2112,2130,2152,2170,2194,2212,2230,2254,2278,2296,2318,2336,2400,2436,2474,2501,2523,2541,2559,2577,2599,2625,2643,2671,2689,2707,2725,2743,2765,2791,2809,2827,2845,2863,2888,2990,3025,3069,3113,3145,3180,3202,3226,3249,3271,3295,3313,3331,3349,3367,3392,3410,3437,3455,3473,3491,3516,3534,3563,3581,3599,3617,3635,3653,3671,3689,3707,3725,3750,3768,3786,3804,3828,3846,3864,3882,3900,3918,3941,3964,3982,4004,4022,4045,4063,4081,4103,4127,4145,4169,4187,4215,4233,4251,4269,4287,4305,4323,4341,4359,4377,4395,4418,4436,4454,4472,4490,4514,4537,4555,4579,4601,4619,4644,4662,4680,4707,4725,4743,4761,4779,4797,4820,4838,4856,4874,4892,4910,4934,4952,4977,4995,5013,5031,5056,5074,5092,5115],{"intervention":56,"totalTrials":93,"cells":94},16,{"EARLY_PHASE1":95,"PHASE1":98,"PHASE2":129,"PHASE3":131,"PHASE4":230,"NA":265},{"trials":96,"activeCount":97},[],0,{"trials":99,"activeCount":97},[100,111,120],{"nctId":101,"briefTitle":102,"status":103,"phases":104,"primaryCompletion":105,"completion":106,"start":107,"enrollment":22,"conditions":108,"interventions":110},"NCT04537429","A Study in Children and Young People With Migraine to Learn What the Body Does to Eptinezumab","COMPLETED",[86],"2022-10-20","2023-08-21","2020-08-04",[109,24],"Migraine in Children",[56],{"nctId":112,"briefTitle":113,"status":103,"phases":114,"primaryCompletion":115,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":119},"NCT04336449","Eptinezumab in Healthy Japanese Subjects",[86],"2020-08-13","2020-04-01",18,[15],[56],{"nctId":121,"briefTitle":122,"status":103,"phases":123,"primaryCompletion":124,"completion":124,"start":125,"enrollment":126,"conditions":127,"interventions":128},"NCT05045781","Safety, Tolerability and Pharmacokinetics of Eptinezumab in Healthy Chinese Subjects",[86],"2021-07-20","2021-04-20",20,[15],[56],{"trials":130,"activeCount":97},[],{"trials":132,"activeCount":229,"soonestReadout":60},[133,144,153,163,174,184,193,201,211,220],{"nctId":134,"briefTitle":135,"status":103,"phases":136,"primaryCompletion":137,"completion":138,"start":139,"enrollment":140,"conditions":141,"interventions":143},"NCT04772742","Eptinezumab in Adults With Migraine and Medication Overuse Headache",[88],"2022-05-23","2022-09-30","2021-02-17",193,[24,142],"Medication Overuse Headache",[56],{"nctId":145,"briefTitle":146,"status":103,"phases":147,"primaryCompletion":148,"completion":148,"start":149,"enrollment":150,"conditions":151,"interventions":152},"NCT05064371","Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan",[88],"2024-06-08","2021-09-21",160,[24],[56],{"nctId":154,"briefTitle":155,"status":103,"phases":156,"primaryCompletion":157,"completion":158,"start":159,"enrollment":160,"conditions":161,"interventions":162},"NCT04921384","Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine",[88],"2024-10-01","2025-02-17","2021-05-29",981,[24],[56],{"nctId":164,"briefTitle":165,"status":103,"phases":166,"primaryCompletion":167,"completion":168,"start":169,"enrollment":170,"conditions":171,"interventions":173},"NCT04688775","Eptinezumab in Participants With Episodic Cluster Headache",[88],"2023-06-14","2023-10-05","2020-12-23",231,[172],"Cluster Headache, Episodic",[56],{"nctId":175,"briefTitle":176,"status":103,"phases":177,"primaryCompletion":178,"completion":178,"start":179,"enrollment":180,"conditions":181,"interventions":183},"NCT05064397","A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH)",[88],"2023-06-29","2021-09-17",131,[182],"Chronic Cluster Headache",[56],{"nctId":58,"briefTitle":59,"status":185,"phases":186,"primaryCompletion":60,"completion":187,"start":188,"enrollment":189,"conditions":190,"interventions":192},"RECRUITING",[88],"2026-10-31","2021-06-30",285,[191],"Chronic Migraine in Children",[56],{"nctId":81,"briefTitle":82,"status":185,"phases":194,"primaryCompletion":83,"completion":195,"start":196,"enrollment":197,"conditions":198,"interventions":200},[88],"2027-08-31","2023-06-08",315,[199],"Episodic Migraine",[56],{"nctId":202,"briefTitle":203,"status":103,"phases":204,"primaryCompletion":205,"completion":206,"start":207,"enrollment":208,"conditions":209,"interventions":210},"NCT04418765","A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive Treatments",[88],"2021-07-15","2022-09-15","2020-06-01",892,[24],[56],{"nctId":212,"briefTitle":213,"status":185,"phases":214,"primaryCompletion":215,"completion":215,"start":216,"enrollment":217,"conditions":218,"interventions":219},"NCT05164172","A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine",[88],"2028-04-30","2021-12-01",600,[24],[56],{"nctId":221,"briefTitle":222,"status":103,"phases":223,"primaryCompletion":224,"completion":224,"start":225,"enrollment":226,"conditions":227,"interventions":228},"NCT04152083","A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine",[88],"2020-07-08","2019-11-07",485,[24],[56],3,{"trials":231,"activeCount":264,"soonestReadout":55},[232,242,249],{"nctId":233,"briefTitle":234,"status":103,"phases":235,"primaryCompletion":236,"completion":237,"start":238,"enrollment":239,"conditions":240,"interventions":241},"NCT05452239","A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache",[89],"2024-10-22","2025-03-13","2022-07-01",608,[24,142],[56],{"nctId":53,"briefTitle":54,"status":243,"phases":244,"primaryCompletion":55,"completion":55,"start":245,"enrollment":246,"conditions":247,"interventions":248},"ACTIVE_NOT_RECRUITING",[89],"2024-12-18",164,[24],[56],{"nctId":250,"briefTitle":251,"status":252,"phases":253,"primaryCompletion":254,"completion":255,"start":256,"enrollment":257,"conditions":258,"interventions":259},"NCT05284019","Real World Effectiveness of Eptinezumab in Participants With Migraine","TERMINATED",[89],"2023-02-17","2023-04-14","2022-03-04",32,[24],[56,260,261,262,263],"Erenumab","Onabotulinumtoxin-A","Fremanezumab","Galcanezumab",1,{"trials":266,"activeCount":97},[],{"intervention":268,"totalTrials":264,"cells":269},"Amlenetug",{"EARLY_PHASE1":270,"PHASE1":272,"PHASE2":274,"PHASE3":276,"PHASE4":289,"NA":291},{"trials":271,"activeCount":97},[],{"trials":273,"activeCount":97},[],{"trials":275,"activeCount":97},[],{"trials":277,"activeCount":264,"soonestReadout":282},[278],{"nctId":279,"briefTitle":280,"status":243,"phases":281,"primaryCompletion":282,"completion":283,"start":284,"enrollment":285,"conditions":286,"interventions":288},"NCT06706622","A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)",[88],"2028-02-17","2029-10-25","2024-12-03",401,[287],"Multiple System Atrophy",[268],{"trials":290,"activeCount":97},[],{"trials":292,"activeCount":97},[],{"intervention":79,"totalTrials":294,"cells":295},7,{"EARLY_PHASE1":296,"PHASE1":298,"PHASE2":356,"PHASE3":368,"PHASE4":370,"NA":372},{"trials":297,"activeCount":97},[],{"trials":299,"activeCount":264,"soonestReadout":78},[300,309,319,331,342,348],{"nctId":301,"briefTitle":302,"status":103,"phases":303,"primaryCompletion":304,"completion":304,"start":305,"enrollment":306,"conditions":307,"interventions":308},"NCT06004180","A Trial Investigating Lu AF28996 in Adult Japanese Participants With Parkinson's Disease (PD)",[86],"2023-11-21","2023-09-12",6,[35],[79],{"nctId":310,"briefTitle":311,"status":103,"phases":312,"primaryCompletion":313,"completion":314,"start":315,"enrollment":316,"conditions":317,"interventions":318},"NCT04291859","Lu AF28996 in Participants With Parkinson's Disease (PD)",[86],"2025-10-14","2026-02-12","2020-02-26",57,[35],[79],{"nctId":320,"briefTitle":321,"status":103,"phases":322,"primaryCompletion":323,"completion":323,"start":324,"enrollment":325,"conditions":326,"interventions":327},"NCT06277609","A Trial Investigating Lu AF28996 in Healthy Adult Participants",[86],"2024-05-19","2024-02-27",22,[32],[79,328,329,330],"Acetylsalicylic Acid","Mefenamic Acid","Amoxicillin\u002Fclavulanic acid",{"nctId":332,"briefTitle":333,"status":103,"phases":334,"primaryCompletion":335,"completion":336,"start":337,"enrollment":338,"conditions":339,"interventions":340},"NCT03565094","Single Dose of Lu AF28996 to Healthy Young Men",[86],"2019-08-17","2019-08-21","2018-05-29",39,[15],[341,79],"Lu AF28996 solution",{"nctId":76,"briefTitle":77,"status":343,"phases":344,"primaryCompletion":78,"completion":78,"start":345,"enrollment":28,"conditions":346,"interventions":347},"NOT_YET_RECRUITING",[86],"2026-03-31",[35],[79],{"nctId":349,"briefTitle":350,"status":103,"phases":351,"primaryCompletion":352,"completion":352,"start":353,"enrollment":11,"conditions":354,"interventions":355},"NCT06337110","A Study Investigating the Movement of Lu AF28996 Into, Through, and Out of the Body of Healthy Men",[86],"2024-05-11","2024-04-10",[32],[79],{"trials":357,"activeCount":264,"soonestReadout":362},[358],{"nctId":359,"briefTitle":360,"status":343,"phases":361,"primaryCompletion":362,"completion":362,"start":363,"enrollment":364,"conditions":365,"interventions":367},"NCT07514858","A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fluctuations",[87],"2028-12-30","2026-06-30",150,[366],"Parkinson's Disease",[79],{"trials":369,"activeCount":97},[],{"trials":371,"activeCount":97},[],{"trials":373,"activeCount":97},[],{"intervention":65,"totalTrials":12,"cells":375},{"EARLY_PHASE1":376,"PHASE1":378,"PHASE2":380,"PHASE3":397,"PHASE4":399,"NA":401},{"trials":377,"activeCount":97},[],{"trials":379,"activeCount":97},[],{"trials":381,"activeCount":12,"soonestReadout":64},[382,389],{"nctId":62,"briefTitle":63,"status":185,"phases":383,"primaryCompletion":64,"completion":384,"start":385,"enrollment":117,"conditions":386,"interventions":388},[87],"2027-11-30","2024-06-19",[387],"Cushing's Disease",[65],{"nctId":67,"briefTitle":68,"status":185,"phases":390,"primaryCompletion":69,"completion":391,"start":392,"enrollment":393,"conditions":394,"interventions":396},[86,87],"2027-12-31","2022-12-19",42,[395],"Congenital Adrenal Hyperplasia",[65],{"trials":398,"activeCount":97},[],{"trials":400,"activeCount":97},[],{"trials":402,"activeCount":97},[],{"intervention":46,"totalTrials":306,"cells":404},{"EARLY_PHASE1":405,"PHASE1":407,"PHASE2":448,"PHASE3":467,"PHASE4":469,"NA":471},{"trials":406,"activeCount":97},[],{"trials":408,"activeCount":97},[409,420,430,439],{"nctId":410,"briefTitle":411,"status":103,"phases":412,"primaryCompletion":413,"completion":414,"start":415,"enrollment":416,"conditions":417,"interventions":419},"NCT05126316","A Trial to Learn More About Repeated Monthly Injections of Lu AG09222 in Participants With Allergies to Grass Pollen",[86],"2022-07-12","2022-08-25","2021-11-01",30,[418],"Allergic Rhinitis",[46],{"nctId":421,"briefTitle":422,"status":103,"phases":423,"primaryCompletion":424,"completion":424,"start":425,"enrollment":426,"conditions":427,"interventions":428},"NCT06578585","A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine",[86],"2025-07-11","2024-09-13",43,[24],[429,46],"Ubrogepant",{"nctId":431,"briefTitle":432,"status":103,"phases":433,"primaryCompletion":434,"completion":435,"start":205,"enrollment":436,"conditions":437,"interventions":438},"NCT04976309","A Single Dose Study of Lu AG09222 in a Headache Model With Healthy Subjects",[86],"2021-09-19","2021-12-10",25,[15],[46],{"nctId":440,"briefTitle":441,"status":103,"phases":442,"primaryCompletion":443,"completion":443,"start":444,"enrollment":445,"conditions":446,"interventions":447},"NCT05304910","A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants",[86],"2022-10-30","2022-03-18",52,[24],[46],{"trials":449,"activeCount":264,"soonestReadout":45},[450,460],{"nctId":451,"briefTitle":452,"status":103,"phases":453,"primaryCompletion":454,"completion":455,"start":456,"enrollment":457,"conditions":458,"interventions":459},"NCT05133323","A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments",[87],"2023-01-19","2023-03-16","2021-11-11",237,[24],[46],{"nctId":43,"briefTitle":44,"status":243,"phases":461,"primaryCompletion":45,"completion":462,"start":463,"enrollment":464,"conditions":465,"interventions":466},[87],"2026-04-30","2024-04-01",874,[24],[46],{"trials":468,"activeCount":97},[],{"trials":470,"activeCount":97},[],{"trials":472,"activeCount":97},[],{"intervention":41,"totalTrials":229,"cells":474},{"EARLY_PHASE1":475,"PHASE1":477,"PHASE2":497,"PHASE3":506,"PHASE4":508,"NA":510},{"trials":476,"activeCount":97},[],{"trials":478,"activeCount":97},[479,488],{"nctId":480,"briefTitle":481,"status":103,"phases":482,"primaryCompletion":483,"completion":483,"start":484,"enrollment":485,"conditions":486,"interventions":487},"NCT03611569","Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease",[86],"2021-07-26","2018-07-25",74,[15,35],[41],{"nctId":489,"briefTitle":490,"status":103,"phases":491,"primaryCompletion":492,"completion":492,"start":493,"enrollment":494,"conditions":495,"interventions":496},"NCT06258720","A Trial Investigating Lu AF82422 in Healthy Chinese and Caucasian Adults",[86],"2024-09-03","2024-03-18",24,[32],[41],{"trials":498,"activeCount":264,"soonestReadout":40},[499],{"nctId":38,"briefTitle":39,"status":243,"phases":500,"primaryCompletion":40,"completion":501,"start":502,"enrollment":503,"conditions":504,"interventions":505},[87],"2028-03-07","2021-11-16",64,[287],[41],{"trials":507,"activeCount":97},[],{"trials":509,"activeCount":97},[],{"trials":511,"activeCount":97},[],{"intervention":51,"totalTrials":12,"cells":513},{"EARLY_PHASE1":514,"PHASE1":516,"PHASE2":534,"PHASE3":536,"PHASE4":538,"NA":540},{"trials":515,"activeCount":97},[],{"trials":517,"activeCount":264,"soonestReadout":50},[518,525],{"nctId":48,"briefTitle":49,"status":243,"phases":519,"primaryCompletion":50,"completion":520,"start":521,"enrollment":126,"conditions":522,"interventions":524},[86],"2026-09-29","2024-09-19",[523],"Thyroid Eye Disease",[51],{"nctId":526,"briefTitle":527,"status":103,"phases":528,"primaryCompletion":529,"completion":529,"start":444,"enrollment":530,"conditions":531,"interventions":532},"NCT05136053","A Study Investigating Lu AG22515 in Healthy Adults",[86],"2023-08-05",58,[32],[51,533],"Immune System Activator",{"trials":535,"activeCount":97},[],{"trials":537,"activeCount":97},[],{"trials":539,"activeCount":97},[],{"trials":541,"activeCount":97},[],{"intervention":74,"totalTrials":264,"cells":543},{"EARLY_PHASE1":544,"PHASE1":546,"PHASE2":556,"PHASE3":558,"PHASE4":560,"NA":562},{"trials":545,"activeCount":97},[],{"trials":547,"activeCount":264,"soonestReadout":73},[548],{"nctId":71,"briefTitle":72,"status":185,"phases":549,"primaryCompletion":73,"completion":550,"start":551,"enrollment":552,"conditions":553,"interventions":555},[86],"2026-12-18","2025-06-13",104,[554],"Narcolepsy",[74],{"trials":557,"activeCount":97},[],{"trials":559,"activeCount":97},[],{"trials":561,"activeCount":97},[],{"trials":563,"activeCount":97},[],{"intervention":565,"totalTrials":306,"cells":566},"Memantine",{"EARLY_PHASE1":567,"PHASE1":569,"PHASE2":580,"PHASE3":582,"PHASE4":604,"NA":638},{"trials":568,"activeCount":97},[],{"trials":570,"activeCount":97},[571],{"nctId":572,"briefTitle":573,"status":103,"phases":574,"primaryCompletion":575,"completion":575,"start":576,"enrollment":503,"conditions":577,"interventions":578},"NCT03670095","Study in Healthy Subjects to Compare Two Tablet Formulations of Memantine (Ebixa®) in Fasted and Fed Conditions",[86],"2018-12-24","2018-08-28",[15],[579,565],"Lactose-free memantine",{"trials":581,"activeCount":97},[],{"trials":583,"activeCount":97},[584,594],{"nctId":585,"briefTitle":586,"status":252,"phases":587,"primaryCompletion":588,"completion":589,"start":590,"enrollment":591,"conditions":592,"interventions":593},"NCT00857233","Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease",[88],"2010-07","2010-10","2004-06",297,[27],[565],{"nctId":595,"briefTitle":596,"status":252,"phases":597,"primaryCompletion":598,"completion":599,"start":600,"enrollment":601,"conditions":602,"interventions":603},"NCT00857649","Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease",[88],"2010-04","2010-09","2003-12",369,[27],[565],{"trials":605,"activeCount":97},[606,616,626],{"nctId":607,"briefTitle":608,"status":103,"phases":609,"primaryCompletion":610,"completion":611,"start":612,"enrollment":613,"conditions":614,"interventions":615},"NCT00862940","A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease",[89],"2009-02","2009-04","2005-09",277,[27],[565],{"nctId":617,"briefTitle":618,"status":103,"phases":619,"primaryCompletion":620,"completion":620,"start":621,"enrollment":622,"conditions":623,"interventions":625},"NCT02553928","Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With Alzheimer",[89],"2016-07","2015-10",62,[624],"Alzheimer Dementia (AD)",[565,565],{"nctId":627,"briefTitle":628,"status":103,"phases":629,"primaryCompletion":630,"completion":631,"start":632,"enrollment":633,"conditions":634,"interventions":637},"NCT00855686","Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies",[89],"2008-12","2009-01","2007-01",199,[635,636],"Parkinson's Disease Dementia","Dementia With Lewy Bodies",[565],{"trials":639,"activeCount":97},[],{"intervention":641,"totalTrials":306,"cells":642},"Sertindole",{"EARLY_PHASE1":643,"PHASE1":645,"PHASE2":647,"PHASE3":649,"PHASE4":699,"NA":708},{"trials":644,"activeCount":97},[],{"trials":646,"activeCount":97},[],{"trials":648,"activeCount":97},[],{"trials":650,"activeCount":97},[651,662,670,680,691],{"nctId":652,"briefTitle":653,"status":103,"phases":654,"primaryCompletion":655,"completion":656,"start":657,"enrollment":658,"conditions":659,"interventions":660},"NCT00864045","Sertindole in Asian Patients With Schizophrenia",[88],"2008-03","2008-05","2007-03",394,[21],[641,661],"Olanzapine",{"nctId":663,"briefTitle":664,"status":103,"phases":665,"primaryCompletion":655,"completion":666,"start":657,"enrollment":667,"conditions":668,"interventions":669},"NCT00759460","Study on Metabolic Parameters of Sertindole in Patients With Schizophrenia",[88],"2008-04",250,[21],[641,661],{"nctId":671,"briefTitle":672,"status":103,"phases":673,"primaryCompletion":674,"completion":674,"start":675,"enrollment":676,"conditions":677,"interventions":678},"NCT00856583","Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use",[88],"2008-02","2002-07",9809,[21],[641,679],"Risperidone",{"nctId":681,"briefTitle":682,"status":103,"phases":683,"primaryCompletion":684,"completion":685,"start":655,"enrollment":686,"conditions":687,"interventions":689},"NCT00654706","Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparator in Patients With Schizophrenia",[88],"2010-01","2010-03",264,[21,688],"Cognition",[641,690],"Quetiapine",{"nctId":692,"briefTitle":693,"status":103,"phases":694,"primaryCompletion":655,"completion":666,"start":695,"enrollment":696,"conditions":697,"interventions":698},"NCT00759421","Exploratory Cognition Study of Sertindole in Patients With Schizophrenia",[88],"2006-10",96,[21],[641,661],{"trials":700,"activeCount":97},[701],{"nctId":702,"briefTitle":703,"status":103,"phases":704,"primaryCompletion":588,"completion":589,"start":705,"enrollment":117,"conditions":706,"interventions":707},"NCT00763438","Safety Study of an Antipsychotic, Sertindole, to Treat Schizophrenia",[89],"2007-11",[21],[641],{"trials":709,"activeCount":97},[],{"intervention":711,"totalTrials":712,"cells":713},"Duloxetine",5,{"EARLY_PHASE1":714,"PHASE1":716,"PHASE2":718,"PHASE3":730,"PHASE4":757,"NA":769},{"trials":715,"activeCount":97},[],{"trials":717,"activeCount":97},[],{"trials":719,"activeCount":97},[720],{"nctId":721,"briefTitle":722,"status":103,"phases":723,"primaryCompletion":724,"completion":611,"start":725,"enrollment":726,"conditions":727,"interventions":728},"NCT00599911","Dose-finding Study With Lu AA24530 in Major Depressive Disorder",[87],"2009-03","2007-10",652,[18],[729,711],"Lu AA24530",{"trials":731,"activeCount":97},[732,740,749],{"nctId":733,"briefTitle":734,"status":103,"phases":735,"primaryCompletion":611,"completion":611,"start":674,"enrollment":736,"conditions":737,"interventions":738},"NCT00635219","Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder",[88],766,[18],[739,739,739,711],"Vortioxetine",{"nctId":741,"briefTitle":742,"status":103,"phases":743,"primaryCompletion":744,"start":745,"enrollment":746,"conditions":747,"interventions":748},"NCT01140906","Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults",[88],"2011-09","2010-05",607,[18],[739,711],{"nctId":750,"briefTitle":751,"status":103,"phases":752,"primaryCompletion":753,"completion":685,"start":631,"enrollment":754,"conditions":755,"interventions":756},"NCT00811252","Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Elderly Patients",[88],"2010-02",453,[18],[739,711],{"trials":758,"activeCount":97},[759],{"nctId":760,"briefTitle":761,"status":103,"phases":762,"primaryCompletion":763,"completion":764,"start":612,"enrollment":765,"conditions":766,"interventions":767},"NCT01148472","Efficacy and Tolerability of Escitalopram and Duloxetine in Outpatients With Major Depressive Disorder",[89],"2006-09","2006-11",294,[18],[768,711],"Escitalopram",{"trials":770,"activeCount":97},[],{"intervention":772,"totalTrials":773,"cells":774},"Nalmefene",4,{"EARLY_PHASE1":775,"PHASE1":777,"PHASE2":779,"PHASE3":781,"PHASE4":807,"NA":819},{"trials":776,"activeCount":97},[],{"trials":778,"activeCount":97},[],{"trials":780,"activeCount":97},[],{"trials":782,"activeCount":97},[783,792,799],{"nctId":784,"briefTitle":785,"status":103,"phases":786,"primaryCompletion":787,"completion":787,"start":724,"enrollment":788,"conditions":789,"interventions":791},"NCT00811941","Safety and Efficacy of Nalmefene in Patients With Alcohol Dependence",[88],"2010-11",665,[790],"Alcohol Dependence",[772],{"nctId":793,"briefTitle":794,"status":103,"phases":795,"primaryCompletion":589,"completion":787,"start":630,"enrollment":796,"conditions":797,"interventions":798},"NCT00811720","Efficacy of Nalmefene in Patients With Alcohol Dependence",[88],598,[790],[772],{"nctId":800,"briefTitle":794,"status":103,"phases":801,"primaryCompletion":802,"completion":803,"start":724,"enrollment":804,"conditions":805,"interventions":806},"NCT00812461",[88],"2011-03","2011-04",678,[790],[772],{"trials":808,"activeCount":97},[809],{"nctId":810,"briefTitle":811,"status":103,"phases":812,"primaryCompletion":813,"start":814,"enrollment":815,"conditions":816,"interventions":817},"NCT02197598","Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use",[89],"2015-12","2014-09",45,[790],[818],"nalmefene",{"trials":820,"activeCount":97},[],{"intervention":768,"totalTrials":773,"cells":822},{"EARLY_PHASE1":823,"PHASE1":825,"PHASE2":833,"PHASE3":835,"PHASE4":837,"NA":858},{"trials":824,"activeCount":97},[],{"trials":826,"activeCount":97},[827],{"nctId":828,"briefTitle":829,"status":103,"phases":830,"primaryCompletion":685,"start":684,"enrollment":257,"conditions":831,"interventions":832},"NCT01395433","Bioequivalence Study Comparing Two Formulations of Escitalopram",[86],[15],[768,768,768],{"trials":834,"activeCount":97},[],{"trials":836,"activeCount":97},[],{"trials":838,"activeCount":97},[839,843,851],{"nctId":760,"briefTitle":761,"status":103,"phases":840,"primaryCompletion":763,"completion":764,"start":612,"enrollment":765,"conditions":841,"interventions":842},[89],[18],[768,711],{"nctId":844,"briefTitle":845,"status":103,"phases":846,"primaryCompletion":847,"completion":685,"start":724,"enrollment":416,"conditions":848,"interventions":850},"NCT00902564","Escitalopram in Patients With Generalized Anxiety Disorder",[89],"2009-12",[849],"Generalized Anxiety Disorder",[768],{"nctId":852,"briefTitle":853,"status":103,"phases":854,"primaryCompletion":847,"completion":685,"start":724,"enrollment":416,"conditions":855,"interventions":857},"NCT00902226","Escitalopram in Patients With Social Anxiety Disorder",[89],[856],"Social Anxiety Disorder",[768],{"trials":859,"activeCount":97},[],{"intervention":861,"totalTrials":264,"cells":862},"Selincro® 18 mg with continuous psychosocial support: Cohort A",{"EARLY_PHASE1":863,"PHASE1":865,"PHASE2":867,"PHASE3":869,"PHASE4":871,"NA":882},{"trials":864,"activeCount":97},[],{"trials":866,"activeCount":97},[],{"trials":868,"activeCount":97},[],{"trials":870,"activeCount":97},[],{"trials":872,"activeCount":97},[873],{"nctId":874,"briefTitle":875,"status":252,"phases":876,"primaryCompletion":877,"completion":877,"start":878,"enrollment":879,"conditions":880,"interventions":881},"NCT02195817","Study of 18 mg Selincro® As-needed Use, in the Treatment of Patients With Alcohol Dependence in Primary Care",[89],"2016-02","2014-08",378,[790],[861],{"trials":883,"activeCount":97},[],{"intervention":885,"totalTrials":264,"cells":886},"Droxidopa",{"EARLY_PHASE1":887,"PHASE1":889,"PHASE2":891,"PHASE3":893,"PHASE4":895,"NA":907},{"trials":888,"activeCount":97},[],{"trials":890,"activeCount":97},[],{"trials":892,"activeCount":97},[],{"trials":894,"activeCount":97},[],{"trials":896,"activeCount":97},[897],{"nctId":898,"briefTitle":899,"status":103,"phases":900,"primaryCompletion":901,"completion":902,"start":903,"enrollment":754,"conditions":904,"interventions":906},"NCT02586623","Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension",[89],"2022-07-21","2022-09-09","2016-02-11",[905],"Symptomatic Neurogenic Orthostatic Hypotension",[885],{"trials":908,"activeCount":97},[],{"intervention":260,"totalTrials":264,"cells":910},{"EARLY_PHASE1":911,"PHASE1":913,"PHASE2":915,"PHASE3":917,"PHASE4":919,"NA":925},{"trials":912,"activeCount":97},[],{"trials":914,"activeCount":97},[],{"trials":916,"activeCount":97},[],{"trials":918,"activeCount":97},[],{"trials":920,"activeCount":97},[921],{"nctId":250,"briefTitle":251,"status":252,"phases":922,"primaryCompletion":254,"completion":255,"start":256,"enrollment":257,"conditions":923,"interventions":924},[89],[24],[56,260,261,262,263],{"trials":926,"activeCount":97},[],{"intervention":261,"totalTrials":264,"cells":928},{"EARLY_PHASE1":929,"PHASE1":931,"PHASE2":933,"PHASE3":935,"PHASE4":937,"NA":943},{"trials":930,"activeCount":97},[],{"trials":932,"activeCount":97},[],{"trials":934,"activeCount":97},[],{"trials":936,"activeCount":97},[],{"trials":938,"activeCount":97},[939],{"nctId":250,"briefTitle":251,"status":252,"phases":940,"primaryCompletion":254,"completion":255,"start":256,"enrollment":257,"conditions":941,"interventions":942},[89],[24],[56,260,261,262,263],{"trials":944,"activeCount":97},[],{"intervention":262,"totalTrials":264,"cells":946},{"EARLY_PHASE1":947,"PHASE1":949,"PHASE2":951,"PHASE3":953,"PHASE4":955,"NA":961},{"trials":948,"activeCount":97},[],{"trials":950,"activeCount":97},[],{"trials":952,"activeCount":97},[],{"trials":954,"activeCount":97},[],{"trials":956,"activeCount":97},[957],{"nctId":250,"briefTitle":251,"status":252,"phases":958,"primaryCompletion":254,"completion":255,"start":256,"enrollment":257,"conditions":959,"interventions":960},[89],[24],[56,260,261,262,263],{"trials":962,"activeCount":97},[],{"intervention":263,"totalTrials":264,"cells":964},{"EARLY_PHASE1":965,"PHASE1":967,"PHASE2":969,"PHASE3":971,"PHASE4":973,"NA":979},{"trials":966,"activeCount":97},[],{"trials":968,"activeCount":97},[],{"trials":970,"activeCount":97},[],{"trials":972,"activeCount":97},[],{"trials":974,"activeCount":97},[975],{"nctId":250,"briefTitle":251,"status":252,"phases":976,"primaryCompletion":254,"completion":255,"start":256,"enrollment":257,"conditions":977,"interventions":978},[89],[24],[56,260,261,262,263],{"trials":980,"activeCount":97},[],{"intervention":982,"totalTrials":264,"cells":983},"Desvenlafaxine",{"EARLY_PHASE1":984,"PHASE1":986,"PHASE2":988,"PHASE3":990,"PHASE4":992,"NA":1004},{"trials":985,"activeCount":97},[],{"trials":987,"activeCount":97},[],{"trials":989,"activeCount":97},[],{"trials":991,"activeCount":97},[],{"trials":993,"activeCount":97},[994],{"nctId":995,"briefTitle":996,"status":103,"phases":997,"primaryCompletion":998,"completion":999,"start":1000,"enrollment":1001,"conditions":1002,"interventions":1003},"NCT04448431","Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression",[89],"2022-01-06","2022-02-04","2020-06-18",605,[18],[739,982],{"trials":1005,"activeCount":97},[],{"intervention":1007,"totalTrials":1008,"cells":1009},"Lu AF35700",11,{"EARLY_PHASE1":1010,"PHASE1":1012,"PHASE2":1092,"PHASE3":1094,"PHASE4":1125,"NA":1127},{"trials":1011,"activeCount":97},[],{"trials":1013,"activeCount":97},[1014,1024,1035,1046,1056,1066,1077,1084],{"nctId":1015,"briefTitle":1016,"status":103,"phases":1017,"primaryCompletion":1018,"completion":1019,"start":1020,"enrollment":28,"conditions":1021,"interventions":1022},"NCT03670082","Study With Lu AF35700 in Healthy Men and Women in Fasting and Fed State",[86],"2018-12-21","2019-01-13","2018-09-05",[15],[1007,1023],"Lu AF35700 iv",{"nctId":1025,"briefTitle":1026,"status":103,"phases":1027,"primaryCompletion":1028,"completion":1029,"start":1030,"enrollment":325,"conditions":1031,"interventions":1033},"NCT03103646","Study Evaluating the Effect of Multiple Doses of Itraconazole on the Drug Lu AF35700 in Healthy Young Men and Women",[86],"2019-04-14","2019-07-19","2017-03-28",[1032],"Cytochrome P450 Interaction",[1007,1034,1034],"Itraconazole",{"nctId":1036,"briefTitle":1037,"status":103,"phases":1038,"primaryCompletion":1039,"completion":1039,"start":1040,"enrollment":494,"conditions":1041,"interventions":1043},"NCT03195946","Effects of Repeated Doses of Lu AF35700 on Drug Metabolizing Enzymes",[86],"2018-01-03","2017-06-16",[1042],"Drug Reactions",[1007,1044,1045],"Midazolam","Cocktail of CYP450 substrates",{"nctId":1047,"briefTitle":1048,"status":103,"phases":1049,"primaryCompletion":1050,"completion":1051,"start":1052,"enrollment":494,"conditions":1053,"interventions":1055},"NCT03189615","Study Investigating the Pharmacokinetic Properties of the Drug Lu AF35700 in Subjects With Liver Impairment and in Healthy Subjects",[86],"2018-02-28","2018-04-23","2017-05-14",[1054],"Hepatic Impairment",[1007],{"nctId":1057,"briefTitle":1058,"status":103,"phases":1059,"primaryCompletion":1060,"completion":1060,"start":1061,"enrollment":1062,"conditions":1063,"interventions":1065},"NCT02901587","Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder",[86],"2018-04-18","2016-09",119,[21,1064],"Schizoaffective Disorder",[1007,1007,690],{"nctId":1067,"briefTitle":1068,"status":252,"phases":1069,"primaryCompletion":1070,"completion":1071,"start":1072,"enrollment":1073,"conditions":1074,"interventions":1076},"NCT03241147","Pharmacokinetics of Lu AF35700 in Subjects With Renal Impairment",[86],"2019-07-17","2019-07-24","2017-07-25",23,[1075],"Renal Failure",[1007],{"nctId":1078,"briefTitle":1079,"status":103,"phases":1080,"primaryCompletion":903,"completion":903,"start":1081,"enrollment":325,"conditions":1082,"interventions":1083},"NCT02333487","Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700",[86],"2014-12-30",[21],[1007],{"nctId":1085,"briefTitle":1086,"status":103,"phases":1087,"primaryCompletion":1088,"start":1089,"enrollment":696,"conditions":1090,"interventions":1091},"NCT02202226","Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia",[86],"2015-02","2013-01",[21],[1007],{"trials":1093,"activeCount":97},[],{"trials":1095,"activeCount":97},[1096,1105,1115],{"nctId":1097,"briefTitle":1098,"status":103,"phases":1099,"primaryCompletion":1100,"completion":1100,"start":1101,"enrollment":1102,"conditions":1103,"interventions":1104},"NCT02892422","Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia",[88],"2019-10-10","2016-08",528,[21],[1007],{"nctId":1106,"briefTitle":1107,"status":252,"phases":1108,"primaryCompletion":1109,"completion":1110,"start":1111,"enrollment":1062,"conditions":1112,"interventions":1114},"NCT03230864","Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia",[88],"2018-12-23","2019-02-05","2017-07-20",[1113],"Treatment-resistant Schizophrenia",[1007,679,661],{"nctId":1116,"briefTitle":1117,"status":103,"phases":1118,"primaryCompletion":1119,"completion":1120,"start":1121,"enrollment":1122,"conditions":1123,"interventions":1124},"NCT02717195","Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia",[88],"2018-08-30","2018-10-08","2016-04",1098,[21],[679,661,1007,1007],{"trials":1126,"activeCount":97},[],{"trials":1128,"activeCount":97},[],{"intervention":1130,"totalTrials":11,"cells":1131},"Gaboxadol",{"EARLY_PHASE1":1132,"PHASE1":1134,"PHASE2":1136,"PHASE3":1138,"PHASE4":1206,"NA":1208},{"trials":1133,"activeCount":97},[],{"trials":1135,"activeCount":97},[],{"trials":1137,"activeCount":97},[],{"trials":1139,"activeCount":97},[1140,1151,1158,1166,1175,1182,1190,1198],{"nctId":1141,"briefTitle":1142,"status":103,"phases":1143,"completion":1144,"start":1145,"enrollment":1146,"conditions":1147,"interventions":1148},"NCT00094627","Adult Primary Insomnia Polysomnographic Study (0928-004)(COMPLETED)",[88],"2006-04","2004-11",465,[30],[1149,1150],"gaboxadol","Comparator: placebo",{"nctId":1152,"briefTitle":1153,"status":103,"phases":1154,"completion":764,"start":590,"enrollment":1155,"conditions":1156,"interventions":1157},"NCT00209846","A Study of Gaboxadol in Primary Insomnia",[88],320,[30],[1130],{"nctId":1159,"briefTitle":1153,"status":103,"phases":1160,"completion":1161,"start":1162,"enrollment":1163,"conditions":1164,"interventions":1165},"NCT00209924",[88],"2005-11","2004-04",505,[30],[1130],{"nctId":1167,"briefTitle":1168,"status":103,"phases":1169,"completion":695,"start":1170,"enrollment":1171,"conditions":1172,"interventions":1174},"NCT00103818","An Investigational Study of MK0928 in Adult Outpatients With Insomnia (0928-014)(COMPLETED)",[88],"2005-02",900,[1173],"Insomnia",[1149,1150],{"nctId":1176,"briefTitle":1153,"status":103,"phases":1177,"completion":1178,"start":1179,"enrollment":217,"conditions":1180,"interventions":1181},"NCT00209963",[88],"2005-03","2003-06",[30],[1130],{"nctId":1183,"briefTitle":1184,"status":103,"phases":1185,"completion":1186,"start":1170,"enrollment":1187,"conditions":1188,"interventions":1189},"NCT00102167","Study of MK0928 in Healthy Adult Volunteers in a Model of Insomnia (0928-006)(COMPLETED)",[88],"2005-12",663,[1173],[1149],{"nctId":1191,"briefTitle":1192,"status":103,"phases":1193,"completion":612,"start":1194,"enrollment":1195,"conditions":1196,"interventions":1197},"NCT00209950","A Prospective Open-Label Extension Study of Gaboxadol in Primary Insomnia",[88],"2004-07",200,[30],[1130],{"nctId":1199,"briefTitle":1200,"status":103,"phases":1201,"completion":590,"start":1202,"enrollment":1203,"conditions":1204,"interventions":1205},"NCT00209937","A Prospective Active-Reference Study of Gaboxadol in Primary Insomnia",[88],"2003-01",675,[30],[1130],{"trials":1207,"activeCount":97},[],{"trials":1209,"activeCount":97},[],{"intervention":1211,"totalTrials":11,"cells":1212},"Brexpiprazole",{"EARLY_PHASE1":1213,"PHASE1":1215,"PHASE2":1217,"PHASE3":1219,"PHASE4":1295,"NA":1297},{"trials":1214,"activeCount":97},[],{"trials":1216,"activeCount":97},[],{"trials":1218,"activeCount":97},[],{"trials":1220,"activeCount":97},[1221,1231,1241,1251,1259,1269,1278,1287],{"nctId":1222,"briefTitle":1223,"status":103,"phases":1224,"primaryCompletion":1225,"completion":1225,"start":1226,"enrollment":1227,"conditions":1228,"interventions":1229},"NCT01810380","Brexpiprazole in Patients With Acute Schizophrenia",[88],"2014-12","2013-03",468,[21],[1211,1230],"Quetiapine extended release",{"nctId":1232,"briefTitle":1233,"status":1234,"phases":1235,"primaryCompletion":1236,"start":1236,"enrollment":97,"conditions":1237,"interventions":1238},"NCT02758067","Comparison of the Effectiveness of Brexpiprazole With That of Risperidone","WITHDRAWN",[88],"2016-06",[21],[1239,1240],"brexpiprazole","risperidone",{"nctId":1242,"briefTitle":1243,"status":103,"phases":1244,"primaryCompletion":1245,"start":1246,"enrollment":1247,"conditions":1248,"interventions":1250},"NCT01942785","Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy",[88],"2014-07","2013-10",55,[18,1249],"Irritability",[1211],{"nctId":1252,"briefTitle":1253,"status":252,"phases":1254,"primaryCompletion":1255,"completion":1255,"start":1246,"enrollment":1256,"conditions":1257,"interventions":1258},"NCT01944969","Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder",[88],"2014-05",26,[18],[1211],{"nctId":1260,"briefTitle":1261,"status":252,"phases":1262,"primaryCompletion":621,"completion":621,"start":1263,"enrollment":1264,"conditions":1265,"interventions":1268},"NCT01987960","Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)",[88],"2013-12",417,[1266,1267],"Post-traumatic Stress Disorder","PTSD",[1211],{"nctId":1270,"briefTitle":1271,"status":103,"phases":1272,"primaryCompletion":1236,"completion":1236,"start":1273,"enrollment":1274,"conditions":1275,"interventions":1276},"NCT01838681","Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment",[88],"2013-06",1986,[18],[1211,1277],"ADT",{"nctId":1279,"briefTitle":1280,"status":103,"phases":1281,"primaryCompletion":878,"completion":878,"start":1282,"enrollment":1283,"conditions":1284,"interventions":1286},"NCT01942733","Study of Brexpiprazole as Adjunctive Treatment of Sleep Disturbances in Patients With Major Depressive Disorder",[88],"2013-09",44,[1285],"Sleep Disturbances",[1211],{"nctId":1288,"briefTitle":1289,"status":103,"phases":1290,"primaryCompletion":813,"completion":813,"start":1291,"enrollment":1292,"conditions":1293,"interventions":1294},"NCT01810783","Brexpiprazole in Patients With Schizophrenia",[88],"2013-07",210,[21],[1211],{"trials":1296,"activeCount":97},[],{"trials":1298,"activeCount":97},[],{"intervention":661,"totalTrials":306,"cells":1300},{"EARLY_PHASE1":1301,"PHASE1":1303,"PHASE2":1305,"PHASE3":1318,"PHASE4":1340,"NA":1342},{"trials":1302,"activeCount":97},[],{"trials":1304,"activeCount":97},[],{"trials":1306,"activeCount":97},[1307],{"nctId":1308,"briefTitle":1309,"status":103,"phases":1310,"primaryCompletion":1311,"completion":1312,"start":1313,"enrollment":1314,"conditions":1315,"interventions":1316},"NCT00770744","Efficacy of Lu 31-130 in Patients With Schizophrenia",[87],"2009-10","2009-11","2008-09",93,[21],[1317,661],"Zicronapine",{"trials":1319,"activeCount":97},[1320,1324,1328,1332,1336],{"nctId":652,"briefTitle":653,"status":103,"phases":1321,"primaryCompletion":655,"completion":656,"start":657,"enrollment":658,"conditions":1322,"interventions":1323},[88],[21],[641,661],{"nctId":663,"briefTitle":664,"status":103,"phases":1325,"primaryCompletion":655,"completion":666,"start":657,"enrollment":667,"conditions":1326,"interventions":1327},[88],[21],[641,661],{"nctId":1106,"briefTitle":1107,"status":252,"phases":1329,"primaryCompletion":1109,"completion":1110,"start":1111,"enrollment":1062,"conditions":1330,"interventions":1331},[88],[1113],[1007,679,661],{"nctId":1116,"briefTitle":1117,"status":103,"phases":1333,"primaryCompletion":1119,"completion":1120,"start":1121,"enrollment":1122,"conditions":1334,"interventions":1335},[88],[21],[679,661,1007,1007],{"nctId":692,"briefTitle":693,"status":103,"phases":1337,"primaryCompletion":655,"completion":666,"start":695,"enrollment":696,"conditions":1338,"interventions":1339},[88],[21],[641,661],{"trials":1341,"activeCount":97},[],{"trials":1343,"activeCount":97},[],{"intervention":690,"totalTrials":712,"cells":1345},{"EARLY_PHASE1":1346,"PHASE1":1348,"PHASE2":1354,"PHASE3":1367,"PHASE4":1388,"NA":1390},{"trials":1347,"activeCount":97},[],{"trials":1349,"activeCount":97},[1350],{"nctId":1057,"briefTitle":1058,"status":103,"phases":1351,"primaryCompletion":1060,"completion":1060,"start":1061,"enrollment":1062,"conditions":1352,"interventions":1353},[86],[21,1064],[1007,1007,690],{"trials":1355,"activeCount":97},[1356],{"nctId":1357,"briefTitle":1358,"status":252,"phases":1359,"primaryCompletion":1360,"completion":1361,"start":630,"enrollment":1362,"conditions":1363,"interventions":1365},"NCT00771134","Efficacy and Safety of Lu AA39959 in Patients With Bipolar Depression",[87],"2009-06","2009-08",105,[1364],"Bipolar Disorder",[1366,690],"Lu AA39959",{"trials":1368,"activeCount":97},[1369,1377,1384],{"nctId":1370,"briefTitle":1371,"status":252,"phases":1372,"primaryCompletion":1361,"completion":1312,"start":655,"enrollment":1373,"conditions":1374,"interventions":1375},"NCT00658645","Efficacy of Bifeprunox in Patients With Schizophrenia",[88],227,[21],[1376,690],"Bifeprunox",{"nctId":1378,"briefTitle":1371,"status":252,"phases":1379,"primaryCompletion":1361,"completion":1312,"start":1380,"enrollment":1381,"conditions":1382,"interventions":1383},"NCT00704509",[88],"2008-06",346,[21],[1376,690],{"nctId":681,"briefTitle":682,"status":103,"phases":1385,"primaryCompletion":684,"completion":685,"start":655,"enrollment":686,"conditions":1386,"interventions":1387},[88],[21,688],[641,690],{"trials":1389,"activeCount":97},[],{"trials":1391,"activeCount":97},[],{"intervention":679,"totalTrials":712,"cells":1393},{"EARLY_PHASE1":1394,"PHASE1":1396,"PHASE2":1398,"PHASE3":1400,"PHASE4":1425,"NA":1427},{"trials":1395,"activeCount":97},[],{"trials":1397,"activeCount":97},[],{"trials":1399,"activeCount":97},[],{"trials":1401,"activeCount":97},[1402,1406,1413,1417,1421],{"nctId":1232,"briefTitle":1233,"status":1234,"phases":1403,"primaryCompletion":1236,"start":1236,"enrollment":97,"conditions":1404,"interventions":1405},[88],[21],[1239,1240],{"nctId":1407,"briefTitle":1408,"status":103,"phases":1409,"primaryCompletion":1410,"start":803,"enrollment":150,"conditions":1411,"interventions":1412},"NCT01295372","Safety and Efficacy of Zicronapine in Patients With Schizophrenia",[88],"2012-10",[21],[1317,679],{"nctId":671,"briefTitle":672,"status":103,"phases":1414,"primaryCompletion":674,"completion":674,"start":675,"enrollment":676,"conditions":1415,"interventions":1416},[88],[21],[641,679],{"nctId":1106,"briefTitle":1107,"status":252,"phases":1418,"primaryCompletion":1109,"completion":1110,"start":1111,"enrollment":1062,"conditions":1419,"interventions":1420},[88],[1113],[1007,679,661],{"nctId":1116,"briefTitle":1117,"status":103,"phases":1422,"primaryCompletion":1119,"completion":1120,"start":1121,"enrollment":1122,"conditions":1423,"interventions":1424},[88],[21],[679,661,1007,1007],{"trials":1426,"activeCount":97},[],{"trials":1428,"activeCount":97},[],{"intervention":1430,"totalTrials":773,"cells":1431},"Idalopirdine",{"EARLY_PHASE1":1432,"PHASE1":1434,"PHASE2":1444,"PHASE3":1446,"PHASE4":1473,"NA":1475},{"trials":1433,"activeCount":97},[],{"trials":1435,"activeCount":97},[1436],{"nctId":1437,"briefTitle":1438,"status":252,"phases":1439,"primaryCompletion":1440,"completion":1440,"start":1441,"enrollment":229,"conditions":1442,"interventions":1443},"NCT03307993","Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease",[86],"2018-02-19","2017-09-22",[27],[1430],{"trials":1445,"activeCount":97},[],{"trials":1447,"activeCount":97},[1448,1457,1466],{"nctId":1449,"briefTitle":1450,"status":103,"phases":1451,"primaryCompletion":1452,"completion":1452,"start":1453,"enrollment":1454,"conditions":1455,"interventions":1456},"NCT02006641","Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil",[88],"2016-12","2014-02",858,[27],[1430],{"nctId":1458,"briefTitle":1459,"status":103,"phases":1460,"primaryCompletion":1461,"completion":1461,"start":1462,"enrollment":1463,"conditions":1464,"interventions":1465},"NCT02006654","Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor",[88],"2017-01","2014-03",734,[27],[1430],{"nctId":1467,"briefTitle":1468,"status":103,"phases":1469,"primaryCompletion":620,"completion":620,"start":1246,"enrollment":1470,"conditions":1471,"interventions":1472},"NCT01955161","Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil",[88],933,[27],[1430],{"trials":1474,"activeCount":97},[],{"trials":1476,"activeCount":97},[],{"intervention":1317,"totalTrials":229,"cells":1478},{"EARLY_PHASE1":1479,"PHASE1":1481,"PHASE2":1483,"PHASE3":1495,"PHASE4":1501,"NA":1503},{"trials":1480,"activeCount":97},[],{"trials":1482,"activeCount":97},[],{"trials":1484,"activeCount":97},[1485,1489],{"nctId":1308,"briefTitle":1309,"status":103,"phases":1486,"primaryCompletion":1311,"completion":1312,"start":1313,"enrollment":1314,"conditions":1487,"interventions":1488},[87],[21],[1317,661],{"nctId":1490,"briefTitle":1309,"status":103,"phases":1491,"primaryCompletion":1311,"completion":1312,"start":657,"enrollment":1492,"conditions":1493,"interventions":1494},"NCT00768326",[87],280,[21],[1317,1317,1317,1317,1317],{"trials":1496,"activeCount":97},[1497],{"nctId":1407,"briefTitle":1408,"status":103,"phases":1498,"primaryCompletion":1410,"start":803,"enrollment":150,"conditions":1499,"interventions":1500},[88],[21],[1317,679],{"trials":1502,"activeCount":97},[],{"trials":1504,"activeCount":97},[],{"intervention":1150,"totalTrials":229,"cells":1506},{"EARLY_PHASE1":1507,"PHASE1":1509,"PHASE2":1511,"PHASE3":1513,"PHASE4":1532,"NA":1534},{"trials":1508,"activeCount":97},[],{"trials":1510,"activeCount":97},[],{"trials":1512,"activeCount":97},[],{"trials":1514,"activeCount":97},[1515,1519,1528],{"nctId":1141,"briefTitle":1142,"status":103,"phases":1516,"completion":1144,"start":1145,"enrollment":1146,"conditions":1517,"interventions":1518},[88],[30],[1149,1150],{"nctId":1520,"briefTitle":1521,"status":103,"phases":1522,"primaryCompletion":1523,"start":1524,"enrollment":1155,"conditions":1525,"interventions":1526},"NCT00095043","Safety of MK0928 on Insomnia in the Elderly (0928-005)(COMPLETED)",[88],"2006-06","2004-10",[1173],[1527,1150],"MK0928, gaboxadol",{"nctId":1167,"briefTitle":1168,"status":103,"phases":1529,"completion":695,"start":1170,"enrollment":1171,"conditions":1530,"interventions":1531},[88],[1173],[1149,1150],{"trials":1533,"activeCount":97},[],{"trials":1535,"activeCount":97},[],{"intervention":1376,"totalTrials":229,"cells":1537},{"EARLY_PHASE1":1538,"PHASE1":1540,"PHASE2":1542,"PHASE3":1544,"PHASE4":1563,"NA":1565},{"trials":1539,"activeCount":97},[],{"trials":1541,"activeCount":97},[],{"trials":1543,"activeCount":97},[],{"trials":1545,"activeCount":97},[1546,1550,1554],{"nctId":1370,"briefTitle":1371,"status":252,"phases":1547,"primaryCompletion":1361,"completion":1312,"start":655,"enrollment":1373,"conditions":1548,"interventions":1549},[88],[21],[1376,690],{"nctId":1378,"briefTitle":1371,"status":252,"phases":1551,"primaryCompletion":1361,"completion":1312,"start":1380,"enrollment":1381,"conditions":1552,"interventions":1553},[88],[21],[1376,690],{"nctId":1555,"briefTitle":1556,"status":252,"phases":1557,"primaryCompletion":1558,"completion":1559,"start":1560,"enrollment":1008,"conditions":1561,"interventions":1562},"NCT00861497","Bifeprunox Extension to Extension Study in Patients With Schizophrenia",[88],"2008-01","2009-07","2006-01",[21],[1376],{"trials":1564,"activeCount":97},[],{"trials":1566,"activeCount":97},[],{"intervention":1568,"totalTrials":229,"cells":1569},"Vortioxetine 10 mg",{"EARLY_PHASE1":1570,"PHASE1":1572,"PHASE2":1584,"PHASE3":1595,"PHASE4":1606,"NA":1608},{"trials":1571,"activeCount":97},[],{"trials":1573,"activeCount":97},[1574],{"nctId":1575,"briefTitle":1576,"status":103,"phases":1577,"primaryCompletion":1578,"start":1453,"enrollment":257,"conditions":1579,"interventions":1581},"NCT02072278","Electroencephalography Study Investigating the Effects of Vortioxetine in Healthy Male Subjects",[86],"2014-11",[1580],"Healthy Men",[1568,1582,1583],"Vortioxetine 20 mg","Escitalopram 15 mg",{"trials":1585,"activeCount":97},[1586],{"nctId":1587,"briefTitle":1588,"status":103,"phases":1589,"primaryCompletion":1061,"completion":1061,"start":1225,"enrollment":1373,"conditions":1590,"interventions":1592},"NCT02327013","Investigating the Effect of Vortioxetine in Adult ADHD Patients",[87],[1591],"Attention Deficit Hyperactivity Disorder",[1593,1594],"vortioxetine 10 mg","vortioxetine 20 mg",{"trials":1596,"activeCount":97},[1597],{"nctId":1598,"briefTitle":1599,"status":103,"phases":1600,"primaryCompletion":877,"completion":877,"start":1601,"enrollment":1602,"conditions":1603,"interventions":1604},"NCT02279966","Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder",[88],"2014-10",152,[18],[1568,1605],"Paroxetine 20 mg",{"trials":1607,"activeCount":97},[],{"trials":1609,"activeCount":97},[],{"intervention":1611,"totalTrials":12,"cells":1612},"Vortioxetine 10 mg\u002Fday",{"EARLY_PHASE1":1613,"PHASE1":1615,"PHASE2":1617,"PHASE3":1619,"PHASE4":1644,"NA":1646},{"trials":1614,"activeCount":97},[],{"trials":1616,"activeCount":97},[],{"trials":1618,"activeCount":97},[],{"trials":1620,"activeCount":97},[1621,1633],{"nctId":1622,"briefTitle":1623,"status":103,"phases":1624,"primaryCompletion":1625,"completion":1625,"start":1626,"enrollment":1627,"conditions":1628,"interventions":1630},"NCT02709655","Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)",[88],"2022-01-21","2016-05-18",683,[1629],"Depressive Disorder, Major",[1611,1631,1632],"Vortioxetine 20 mg\u002Fday","Fluoxetine 20mg\u002Fday",{"nctId":1634,"briefTitle":1635,"status":103,"phases":1636,"primaryCompletion":1637,"completion":1638,"start":1639,"enrollment":1640,"conditions":1641,"interventions":1642},"NCT02709746","Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)",[88],"2019-07-02","2019-07-30","2016-05",784,[1629],[1611,1631,1643],"Fluoxetine 20 mg\u002Fday",{"trials":1645,"activeCount":97},[],{"trials":1647,"activeCount":97},[],{"intervention":1631,"totalTrials":12,"cells":1649},{"EARLY_PHASE1":1650,"PHASE1":1652,"PHASE2":1654,"PHASE3":1656,"PHASE4":1666,"NA":1668},{"trials":1651,"activeCount":97},[],{"trials":1653,"activeCount":97},[],{"trials":1655,"activeCount":97},[],{"trials":1657,"activeCount":97},[1658,1662],{"nctId":1622,"briefTitle":1623,"status":103,"phases":1659,"primaryCompletion":1625,"completion":1625,"start":1626,"enrollment":1627,"conditions":1660,"interventions":1661},[88],[1629],[1611,1631,1632],{"nctId":1634,"briefTitle":1635,"status":103,"phases":1663,"primaryCompletion":1637,"completion":1638,"start":1639,"enrollment":1640,"conditions":1664,"interventions":1665},[88],[1629],[1611,1631,1643],{"trials":1667,"activeCount":97},[],{"trials":1669,"activeCount":97},[],{"intervention":1671,"totalTrials":12,"cells":1672},"Venlafaxine extended release",{"EARLY_PHASE1":1673,"PHASE1":1675,"PHASE2":1677,"PHASE3":1687,"PHASE4":1697,"NA":1699},{"trials":1674,"activeCount":97},[],{"trials":1676,"activeCount":97},[],{"trials":1678,"activeCount":97},[1679],{"nctId":1680,"briefTitle":1681,"status":252,"phases":1682,"primaryCompletion":631,"completion":610,"start":1313,"enrollment":1683,"conditions":1684,"interventions":1685},"NCT00766870","Efficacy and Safety of Lu AA34893 in Patients With Major Depressive Disorder",[87],35,[18],[1686,1671],"Lu AA34893",{"trials":1688,"activeCount":97},[1689],{"nctId":1690,"briefTitle":1691,"status":103,"phases":1692,"primaryCompletion":1246,"start":1693,"enrollment":1694,"conditions":1695,"interventions":1696},"NCT01571453","Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries",[88],"2012-05",437,[18],[739,1671],{"trials":1698,"activeCount":97},[],{"trials":1700,"activeCount":97},[],{"intervention":1702,"totalTrials":12,"cells":1703},"Rasagiline",{"EARLY_PHASE1":1704,"PHASE1":1706,"PHASE2":1716,"PHASE3":1718,"PHASE4":1729,"NA":1731},{"trials":1705,"activeCount":97},[],{"trials":1707,"activeCount":97},[1708],{"nctId":1709,"briefTitle":1710,"status":103,"phases":1711,"primaryCompletion":1712,"start":1693,"enrollment":1713,"conditions":1714,"interventions":1715},"NCT01652313","Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and Women",[86],"2012-06",12,[366],[1702],{"trials":1717,"activeCount":97},[],{"trials":1719,"activeCount":97},[1720],{"nctId":1721,"briefTitle":1722,"status":103,"phases":1723,"primaryCompletion":1263,"start":1724,"enrollment":1725,"conditions":1726,"interventions":1727},"NCT01556165","Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China",[88],"2012-04",130,[366],[1728],"rasagiline",{"trials":1730,"activeCount":97},[],{"trials":1732,"activeCount":97},[],{"intervention":1734,"totalTrials":12,"cells":1735},"Desmoteplase",{"EARLY_PHASE1":1736,"PHASE1":1738,"PHASE2":1740,"PHASE3":1742,"PHASE4":1759,"NA":1761},{"trials":1737,"activeCount":97},[],{"trials":1739,"activeCount":97},[],{"trials":1741,"activeCount":97},[],{"trials":1743,"activeCount":97},[1744,1752],{"nctId":1745,"briefTitle":1746,"status":252,"phases":1747,"primaryCompletion":1601,"start":611,"enrollment":1748,"conditions":1749,"interventions":1751},"NCT00856661","Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)",[88],270,[1750],"Stroke",[1734],{"nctId":1753,"briefTitle":1754,"status":103,"phases":1755,"primaryCompletion":1245,"start":630,"enrollment":1756,"conditions":1757,"interventions":1758},"NCT00790920","Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke",[88],492,[1750],[1734],{"trials":1760,"activeCount":97},[],{"trials":1762,"activeCount":97},[],{"intervention":1764,"totalTrials":12,"cells":1765},"Vortioxetine 10-20 mg",{"EARLY_PHASE1":1766,"PHASE1":1768,"PHASE2":1770,"PHASE3":1772,"PHASE4":1791,"NA":1793},{"trials":1767,"activeCount":97},[],{"trials":1769,"activeCount":97},[],{"trials":1771,"activeCount":97},[],{"trials":1773,"activeCount":97},[1774,1783],{"nctId":1775,"briefTitle":1776,"status":103,"phases":1777,"primaryCompletion":1778,"completion":1778,"start":1225,"enrollment":1779,"conditions":1780,"interventions":1781},"NCT02272517","Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder",[88],"2016-03",101,[18],[1764,1782],"Escitalopram 10-20 mg",{"nctId":1784,"briefTitle":1785,"status":103,"phases":1786,"primaryCompletion":1121,"completion":1121,"start":1601,"enrollment":1787,"conditions":1788,"interventions":1789},"NCT02279953","Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder",[88],151,[18],[1764,1790],"SSRI",{"trials":1792,"activeCount":97},[],{"trials":1794,"activeCount":97},[],{"intervention":1796,"totalTrials":12,"cells":1797},"Azilect®",{"EARLY_PHASE1":1798,"PHASE1":1800,"PHASE2":1802,"PHASE3":1804,"PHASE4":1822,"NA":1824},{"trials":1799,"activeCount":97},[],{"trials":1801,"activeCount":97},[],{"trials":1803,"activeCount":97},[],{"trials":1805,"activeCount":97},[1806,1814],{"nctId":1807,"briefTitle":1808,"status":103,"phases":1809,"primaryCompletion":1273,"completion":1273,"start":1810,"enrollment":1811,"conditions":1812,"interventions":1813},"NCT01479530","Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China",[88],"2011-12",321,[366],[1796],{"nctId":1815,"briefTitle":1816,"status":103,"phases":1817,"primaryCompletion":1712,"start":1818,"enrollment":1819,"conditions":1820,"interventions":1821},"NCT01268891","Study of Azilect® (Rasagiline) in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations in Korea",[88],"2011-01",132,[366],[1796],{"trials":1823,"activeCount":97},[],{"trials":1825,"activeCount":97},[],{"intervention":1277,"totalTrials":12,"cells":1827},{"EARLY_PHASE1":1828,"PHASE1":1830,"PHASE2":1832,"PHASE3":1834,"PHASE4":1849,"NA":1851},{"trials":1829,"activeCount":97},[],{"trials":1831,"activeCount":97},[],{"trials":1833,"activeCount":97},[],{"trials":1835,"activeCount":97},[1836,1845],{"nctId":1837,"briefTitle":1838,"status":103,"phases":1839,"primaryCompletion":1236,"completion":1236,"start":1840,"enrollment":1819,"conditions":1841,"interventions":1843},"NCT02400346","Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment",[88],"2015-03",[1842],"Major Depression Disorder",[1844,1277],"Adjunct brexpiprazole",{"nctId":1270,"briefTitle":1271,"status":103,"phases":1846,"primaryCompletion":1236,"completion":1236,"start":1273,"enrollment":1274,"conditions":1847,"interventions":1848},[88],[18],[1211,1277],{"trials":1850,"activeCount":97},[],{"trials":1852,"activeCount":97},[],{"intervention":1854,"totalTrials":12,"cells":1855},"Lu AA21004",{"EARLY_PHASE1":1856,"PHASE1":1858,"PHASE2":1867,"PHASE3":1869,"PHASE4":1880,"NA":1882},{"trials":1857,"activeCount":97},[],{"trials":1859,"activeCount":97},[1860],{"nctId":1861,"briefTitle":1862,"status":103,"phases":1863,"primaryCompletion":1864,"start":1410,"enrollment":93,"conditions":1865,"interventions":1866},"NCT01676571","Pharmacokinetic Properties of Lu AA21004 (Vortioxetine) in Healthy Young Chinese Men and Women",[86],"2012-11",[15],[1854],{"trials":1868,"activeCount":97},[],{"trials":1870,"activeCount":97},[1871],{"nctId":1872,"briefTitle":1873,"status":103,"phases":1874,"primaryCompletion":1875,"completion":588,"start":1876,"enrollment":1877,"conditions":1878,"interventions":1879},"NCT00788034","Relapse-prevention Study With Lu AA21004 (Vortioxetine) in Patients With Generalized Anxiety Disorder",[88],"2010-06","2008-10",459,[849],[1854],{"trials":1881,"activeCount":97},[],{"trials":1883,"activeCount":97},[],{"intervention":1885,"totalTrials":12,"cells":1886},"Clobazam",{"EARLY_PHASE1":1887,"PHASE1":1889,"PHASE2":1891,"PHASE3":1893,"PHASE4":1909,"NA":1911},{"trials":1888,"activeCount":97},[],{"trials":1890,"activeCount":97},[],{"trials":1892,"activeCount":97},[],{"trials":1894,"activeCount":97},[1895,1902],{"nctId":1896,"briefTitle":1897,"status":252,"phases":1898,"primaryCompletion":621,"completion":621,"start":1840,"enrollment":229,"conditions":1899,"interventions":1901},"NCT02187809","Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome",[88],[1900],"Dravet Syndrome",[1885],{"nctId":1903,"briefTitle":1904,"status":1234,"phases":1905,"primaryCompletion":1906,"completion":1906,"start":1840,"enrollment":97,"conditions":1907,"interventions":1908},"NCT02174094","Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome",[88],"2015-08",[1900],[1885],{"trials":1910,"activeCount":97},[],{"trials":1912,"activeCount":97},[],{"intervention":1632,"totalTrials":264,"cells":1914},{"EARLY_PHASE1":1915,"PHASE1":1917,"PHASE2":1919,"PHASE3":1921,"PHASE4":1927,"NA":1929},{"trials":1916,"activeCount":97},[],{"trials":1918,"activeCount":97},[],{"trials":1920,"activeCount":97},[],{"trials":1922,"activeCount":97},[1923],{"nctId":1622,"briefTitle":1623,"status":103,"phases":1924,"primaryCompletion":1625,"completion":1625,"start":1626,"enrollment":1627,"conditions":1925,"interventions":1926},[88],[1629],[1611,1631,1632],{"trials":1928,"activeCount":97},[],{"trials":1930,"activeCount":97},[],{"intervention":1932,"totalTrials":264,"cells":1933},"MK0928, gaboxadol \u002F Duration of Treatment - 1 year",{"EARLY_PHASE1":1934,"PHASE1":1936,"PHASE2":1938,"PHASE3":1940,"PHASE4":1950,"NA":1952},{"trials":1935,"activeCount":97},[],{"trials":1937,"activeCount":97},[],{"trials":1939,"activeCount":97},[],{"trials":1941,"activeCount":97},[1942],{"nctId":1943,"briefTitle":1944,"status":103,"phases":1945,"primaryCompletion":1946,"completion":1946,"start":1524,"enrollment":217,"conditions":1947,"interventions":1948},"NCT00095069","Efficacy and Safety of MK0928 for Insomnia in Adults (0928-003)(COMPLETED)",[88],"2007-02",[1173],[1932,1949],"Comparator: placebo \u002F Duration of Treatment -1 year",{"trials":1951,"activeCount":97},[],{"trials":1953,"activeCount":97},[],{"intervention":1949,"totalTrials":264,"cells":1955},{"EARLY_PHASE1":1956,"PHASE1":1958,"PHASE2":1960,"PHASE3":1962,"PHASE4":1968,"NA":1970},{"trials":1957,"activeCount":97},[],{"trials":1959,"activeCount":97},[],{"trials":1961,"activeCount":97},[],{"trials":1963,"activeCount":97},[1964],{"nctId":1943,"briefTitle":1944,"status":103,"phases":1965,"primaryCompletion":1946,"completion":1946,"start":1524,"enrollment":217,"conditions":1966,"interventions":1967},[88],[1173],[1932,1949],{"trials":1969,"activeCount":97},[],{"trials":1971,"activeCount":97},[],{"intervention":1973,"totalTrials":264,"cells":1974},"MK0928 \u002F Duration of Treatment : 8 Weeks",{"EARLY_PHASE1":1975,"PHASE1":1977,"PHASE2":1979,"PHASE3":1981,"PHASE4":1990,"NA":1992},{"trials":1976,"activeCount":97},[],{"trials":1978,"activeCount":97},[],{"trials":1980,"activeCount":97},[],{"trials":1982,"activeCount":97},[1983],{"nctId":1984,"briefTitle":1985,"status":252,"phases":1986,"primaryCompletion":657,"start":763,"enrollment":1987,"conditions":1988,"interventions":1989},"NCT00420810","Adult Polysomnography Primary Insomnia Cross Over Study (0928-049)(TERMINATED)",[88],138,[30],[1973],{"trials":1991,"activeCount":97},[],{"trials":1993,"activeCount":97},[],{"intervention":1782,"totalTrials":264,"cells":1995},{"EARLY_PHASE1":1996,"PHASE1":1998,"PHASE2":2000,"PHASE3":2002,"PHASE4":2008,"NA":2010},{"trials":1997,"activeCount":97},[],{"trials":1999,"activeCount":97},[],{"trials":2001,"activeCount":97},[],{"trials":2003,"activeCount":97},[2004],{"nctId":1775,"briefTitle":1776,"status":103,"phases":2005,"primaryCompletion":1778,"completion":1778,"start":1225,"enrollment":1779,"conditions":2006,"interventions":2007},[88],[18],[1764,1782],{"trials":2009,"activeCount":97},[],{"trials":2011,"activeCount":97},[],{"intervention":2013,"totalTrials":264,"cells":2014},"Brexpiprazole 1 mg",{"EARLY_PHASE1":2015,"PHASE1":2017,"PHASE2":2019,"PHASE3":2021,"PHASE4":2032,"NA":2034},{"trials":2016,"activeCount":97},[],{"trials":2018,"activeCount":97},[],{"trials":2020,"activeCount":97},[],{"trials":2022,"activeCount":97},[2023],{"nctId":2024,"briefTitle":2025,"status":252,"phases":2026,"primaryCompletion":1255,"completion":1255,"start":2027,"enrollment":2028,"conditions":2029,"interventions":2030},"NCT01837797","Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment",[88],"2013-04",129,[18],[2013,2031],"Brexpiprazole 3 mg",{"trials":2033,"activeCount":97},[],{"trials":2035,"activeCount":97},[],{"intervention":2031,"totalTrials":264,"cells":2037},{"EARLY_PHASE1":2038,"PHASE1":2040,"PHASE2":2042,"PHASE3":2044,"PHASE4":2050,"NA":2052},{"trials":2039,"activeCount":97},[],{"trials":2041,"activeCount":97},[],{"trials":2043,"activeCount":97},[],{"trials":2045,"activeCount":97},[2046],{"nctId":2024,"briefTitle":2025,"status":252,"phases":2047,"primaryCompletion":1255,"completion":1255,"start":2027,"enrollment":2028,"conditions":2048,"interventions":2049},[88],[18],[2013,2031],{"trials":2051,"activeCount":97},[],{"trials":2053,"activeCount":97},[],{"intervention":1230,"totalTrials":264,"cells":2055},{"EARLY_PHASE1":2056,"PHASE1":2058,"PHASE2":2060,"PHASE3":2062,"PHASE4":2068,"NA":2070},{"trials":2057,"activeCount":97},[],{"trials":2059,"activeCount":97},[],{"trials":2061,"activeCount":97},[],{"trials":2063,"activeCount":97},[2064],{"nctId":1222,"briefTitle":1223,"status":103,"phases":2065,"primaryCompletion":1225,"completion":1225,"start":1226,"enrollment":1227,"conditions":2066,"interventions":2067},[88],[21],[1211,1230],{"trials":2069,"activeCount":97},[],{"trials":2071,"activeCount":97},[],{"intervention":1527,"totalTrials":264,"cells":2073},{"EARLY_PHASE1":2074,"PHASE1":2076,"PHASE2":2078,"PHASE3":2080,"PHASE4":2086,"NA":2088},{"trials":2075,"activeCount":97},[],{"trials":2077,"activeCount":97},[],{"trials":2079,"activeCount":97},[],{"trials":2081,"activeCount":97},[2082],{"nctId":1520,"briefTitle":1521,"status":103,"phases":2083,"primaryCompletion":1523,"start":1524,"enrollment":1155,"conditions":2084,"interventions":2085},[88],[1173],[1527,1150],{"trials":2087,"activeCount":97},[],{"trials":2089,"activeCount":97},[],{"intervention":2091,"totalTrials":264,"cells":2092},"Aripiprazole once-monthly",{"EARLY_PHASE1":2093,"PHASE1":2095,"PHASE2":2097,"PHASE3":2099,"PHASE4":2108,"NA":2110},{"trials":2094,"activeCount":97},[],{"trials":2096,"activeCount":97},[],{"trials":2098,"activeCount":97},[],{"trials":2100,"activeCount":97},[2101],{"nctId":2102,"briefTitle":2103,"status":103,"phases":2104,"primaryCompletion":1840,"completion":1840,"start":1246,"enrollment":2105,"conditions":2106,"interventions":2107},"NCT01959035","Aripiprazole Once-monthly in Patients With Schizophrenia",[88],88,[21],[2091],{"trials":2109,"activeCount":97},[],{"trials":2111,"activeCount":97},[],{"intervention":1643,"totalTrials":264,"cells":2113},{"EARLY_PHASE1":2114,"PHASE1":2116,"PHASE2":2118,"PHASE3":2120,"PHASE4":2126,"NA":2128},{"trials":2115,"activeCount":97},[],{"trials":2117,"activeCount":97},[],{"trials":2119,"activeCount":97},[],{"trials":2121,"activeCount":97},[2122],{"nctId":1634,"briefTitle":1635,"status":103,"phases":2123,"primaryCompletion":1637,"completion":1638,"start":1639,"enrollment":1640,"conditions":2124,"interventions":2125},[88],[1629],[1611,1631,1643],{"trials":2127,"activeCount":97},[],{"trials":2129,"activeCount":97},[],{"intervention":2131,"totalTrials":264,"cells":2132},"MK0928, gaboxadol \u002F Duration of Treatment: 10 months",{"EARLY_PHASE1":2133,"PHASE1":2135,"PHASE2":2137,"PHASE3":2139,"PHASE4":2148,"NA":2150},{"trials":2134,"activeCount":97},[],{"trials":2136,"activeCount":97},[],{"trials":2138,"activeCount":97},[],{"trials":2140,"activeCount":97},[2141],{"nctId":2142,"briefTitle":2143,"status":1234,"phases":2144,"start":2145,"enrollment":97,"conditions":2146,"interventions":2147},"NCT00102154","An Investigational Drug Study in Healthy Adult Volunteers in a Model of Insomnia (0928-007)",[88],"2005-01",[1173],[2131],{"trials":2149,"activeCount":97},[],{"trials":2151,"activeCount":97},[],{"intervention":1844,"totalTrials":264,"cells":2153},{"EARLY_PHASE1":2154,"PHASE1":2156,"PHASE2":2158,"PHASE3":2160,"PHASE4":2166,"NA":2168},{"trials":2155,"activeCount":97},[],{"trials":2157,"activeCount":97},[],{"trials":2159,"activeCount":97},[],{"trials":2161,"activeCount":97},[2162],{"nctId":1837,"briefTitle":1838,"status":103,"phases":2163,"primaryCompletion":1236,"completion":1236,"start":1840,"enrollment":1819,"conditions":2164,"interventions":2165},[88],[1842],[1844,1277],{"trials":2167,"activeCount":97},[],{"trials":2169,"activeCount":97},[],{"intervention":2171,"totalTrials":264,"cells":2172},"Aripiprazole and aripiprazole once-monthly",{"EARLY_PHASE1":2173,"PHASE1":2175,"PHASE2":2177,"PHASE3":2179,"PHASE4":2190,"NA":2192},{"trials":2174,"activeCount":97},[],{"trials":2176,"activeCount":97},[],{"trials":2178,"activeCount":97},[],{"trials":2180,"activeCount":97},[2181],{"nctId":2182,"briefTitle":2183,"status":103,"phases":2184,"primaryCompletion":814,"completion":814,"start":2185,"enrollment":2186,"conditions":2187,"interventions":2188},"NCT01795547","Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia",[88],"2013-02",295,[21],[2171,2189],"Paliperidone and paliperidone palmitate",{"trials":2191,"activeCount":97},[],{"trials":2193,"activeCount":97},[],{"intervention":2189,"totalTrials":264,"cells":2195},{"EARLY_PHASE1":2196,"PHASE1":2198,"PHASE2":2200,"PHASE3":2202,"PHASE4":2208,"NA":2210},{"trials":2197,"activeCount":97},[],{"trials":2199,"activeCount":97},[],{"trials":2201,"activeCount":97},[],{"trials":2203,"activeCount":97},[2204],{"nctId":2182,"briefTitle":2183,"status":103,"phases":2205,"primaryCompletion":814,"completion":814,"start":2185,"enrollment":2186,"conditions":2206,"interventions":2207},[88],[21],[2171,2189],{"trials":2209,"activeCount":97},[],{"trials":2211,"activeCount":97},[],{"intervention":1790,"totalTrials":264,"cells":2213},{"EARLY_PHASE1":2214,"PHASE1":2216,"PHASE2":2218,"PHASE3":2220,"PHASE4":2226,"NA":2228},{"trials":2215,"activeCount":97},[],{"trials":2217,"activeCount":97},[],{"trials":2219,"activeCount":97},[],{"trials":2221,"activeCount":97},[2222],{"nctId":1784,"briefTitle":1785,"status":103,"phases":2223,"primaryCompletion":1121,"completion":1121,"start":1601,"enrollment":1787,"conditions":2224,"interventions":2225},[88],[18],[1764,1790],{"trials":2227,"activeCount":97},[],{"trials":2229,"activeCount":97},[],{"intervention":2231,"totalTrials":264,"cells":2232},"Idalopirdine 60 mg",{"EARLY_PHASE1":2233,"PHASE1":2235,"PHASE2":2237,"PHASE3":2239,"PHASE4":2250,"NA":2252},{"trials":2234,"activeCount":97},[],{"trials":2236,"activeCount":97},[],{"trials":2238,"activeCount":97},[],{"trials":2240,"activeCount":97},[2241],{"nctId":2242,"briefTitle":2243,"status":103,"phases":2244,"primaryCompletion":2245,"completion":2245,"start":2246,"enrollment":2247,"conditions":2248,"interventions":2249},"NCT02079246","Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease",[88],"2017-07-06","2014-04-07",1463,[27],[2231],{"trials":2251,"activeCount":97},[],{"trials":2253,"activeCount":97},[],{"intervention":2255,"totalTrials":264,"cells":2256},"Agomelatine",{"EARLY_PHASE1":2257,"PHASE1":2259,"PHASE2":2261,"PHASE3":2263,"PHASE4":2274,"NA":2276},{"trials":2258,"activeCount":97},[],{"trials":2260,"activeCount":97},[],{"trials":2262,"activeCount":97},[],{"trials":2264,"activeCount":97},[2265],{"nctId":2266,"briefTitle":2267,"status":103,"phases":2268,"primaryCompletion":2269,"start":2270,"enrollment":2271,"conditions":2272,"interventions":2273},"NCT01488071","A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication",[88],"2012-12","2012-01",495,[18],[739,2255],{"trials":2275,"activeCount":97},[],{"trials":2277,"activeCount":97},[],{"intervention":1605,"totalTrials":264,"cells":2279},{"EARLY_PHASE1":2280,"PHASE1":2282,"PHASE2":2284,"PHASE3":2286,"PHASE4":2292,"NA":2294},{"trials":2281,"activeCount":97},[],{"trials":2283,"activeCount":97},[],{"trials":2285,"activeCount":97},[],{"trials":2287,"activeCount":97},[2288],{"nctId":1598,"briefTitle":1599,"status":103,"phases":2289,"primaryCompletion":877,"completion":877,"start":1601,"enrollment":1602,"conditions":2290,"interventions":2291},[88],[18],[1568,1605],{"trials":2293,"activeCount":97},[],{"trials":2295,"activeCount":97},[],{"intervention":2297,"totalTrials":264,"cells":2298},"MK0928, gaboxadol \u002F Duration of Treatment - 6 weeks",{"EARLY_PHASE1":2299,"PHASE1":2301,"PHASE2":2303,"PHASE3":2305,"PHASE4":2314,"NA":2316},{"trials":2300,"activeCount":97},[],{"trials":2302,"activeCount":97},[],{"trials":2304,"activeCount":97},[],{"trials":2306,"activeCount":97},[2307],{"nctId":2308,"briefTitle":2309,"status":252,"phases":2310,"primaryCompletion":657,"completion":657,"start":1145,"enrollment":1146,"conditions":2311,"interventions":2312},"NCT00094666","Elderly Primary Insomnia Polysomnographic Study (0928-002)(TERMINATED)",[88],[30],[2297,2313],"Comparator: placebo \u002F Duration of Treatment - 6 weeks",{"trials":2315,"activeCount":97},[],{"trials":2317,"activeCount":97},[],{"intervention":2313,"totalTrials":264,"cells":2319},{"EARLY_PHASE1":2320,"PHASE1":2322,"PHASE2":2324,"PHASE3":2326,"PHASE4":2332,"NA":2334},{"trials":2321,"activeCount":97},[],{"trials":2323,"activeCount":97},[],{"trials":2325,"activeCount":97},[],{"trials":2327,"activeCount":97},[2328],{"nctId":2308,"briefTitle":2309,"status":252,"phases":2329,"primaryCompletion":657,"completion":657,"start":1145,"enrollment":1146,"conditions":2330,"interventions":2331},[88],[30],[2297,2313],{"trials":2333,"activeCount":97},[],{"trials":2335,"activeCount":97},[],{"intervention":2337,"totalTrials":306,"cells":2338},"Lu AF11167",{"EARLY_PHASE1":2339,"PHASE1":2341,"PHASE2":2373,"PHASE3":2394,"PHASE4":2396,"NA":2398},{"trials":2340,"activeCount":97},[],{"trials":2342,"activeCount":97},[2343,2350,2356,2362],{"nctId":2344,"briefTitle":2345,"status":103,"phases":2346,"primaryCompletion":1088,"start":1246,"enrollment":2347,"conditions":2348,"interventions":2349},"NCT02202213","Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia",[86],47,[21],[2337],{"nctId":2351,"briefTitle":2352,"status":103,"phases":2353,"primaryCompletion":1088,"start":1245,"enrollment":126,"conditions":2354,"interventions":2355},"NCT02199431","Study to Evaluate the Effect of a Known and Marketed Product, Itraconazole (Mycosis Treatment) on Lu AF11167 Entering the Body and Subsequently Elimination. The Study is a Drug-drug Interaction Study in Healthy Volunteers.",[86],[15],[2337,1034],{"nctId":2357,"briefTitle":2358,"status":103,"phases":2359,"primaryCompletion":1840,"start":878,"enrollment":22,"conditions":2360,"interventions":2361},"NCT02260830","Pharmacokinetic Properties of Various Modified Release Tablet Formulations of Lu AF11167",[86],[21],[2337],{"nctId":2363,"briefTitle":2364,"status":103,"phases":2365,"primaryCompletion":2366,"completion":2366,"start":2367,"enrollment":2368,"conditions":2369,"interventions":2370},"NCT04104503","A Study Investigating Tablet Formulations of Lu AF11167 in Healthy Subjects",[86],"2020-04-09","2019-09-17",33,[15],[2337,2371,2372],"[14C]-Lu AF11167","Lu AF11167 MR tablet prototype formulation selected from part A or 1 mg modified release",{"trials":2374,"activeCount":97},[2375,2385],{"nctId":2376,"briefTitle":2377,"status":252,"phases":2378,"primaryCompletion":2379,"completion":2380,"start":2381,"enrollment":2382,"conditions":2383,"interventions":2384},"NCT03793712","Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia",[87],"2020-08-20","2020-09-03","2018-12-27",168,[21],[2337,2337],{"nctId":2386,"briefTitle":2387,"status":252,"phases":2388,"primaryCompletion":2389,"completion":2390,"start":2391,"enrollment":696,"conditions":2392,"interventions":2393},"NCT03929497","Flexible-dose Long-term Extension Study of Lu AF11167 in Patients With Schizophrenia With Prominent Negative Symptoms",[87],"2020-09-01","2020-09-14","2019-04-22",[21],[2337],{"trials":2395,"activeCount":97},[],{"trials":2397,"activeCount":97},[],{"trials":2399,"activeCount":97},[],{"intervention":2401,"totalTrials":229,"cells":2402},"Lu AE58054",{"EARLY_PHASE1":2403,"PHASE1":2405,"PHASE2":2413,"PHASE3":2430,"PHASE4":2432,"NA":2434},{"trials":2404,"activeCount":97},[],{"trials":2406,"activeCount":97},[2407],{"nctId":2408,"briefTitle":2409,"status":103,"phases":2410,"primaryCompletion":1453,"start":1263,"enrollment":28,"conditions":2411,"interventions":2412},"NCT02019394","Absolute Bioavailability of Lu AE58054 in Healthy Subjects",[86],[15],[2401],{"trials":2414,"activeCount":97},[2415,2423],{"nctId":2416,"briefTitle":2417,"status":103,"phases":2418,"primaryCompletion":684,"completion":753,"start":2419,"enrollment":2420,"conditions":2421,"interventions":2422},"NCT00810667","Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Patients With Schizophrenia",[87],"2008-11",124,[21,688],[2401],{"nctId":2424,"briefTitle":2425,"status":103,"phases":2426,"primaryCompletion":1810,"start":847,"enrollment":2427,"conditions":2428,"interventions":2429},"NCT01019421","Lu AE58054 Added to Donepezil for the Treatment for Moderate Alzheimer's Disease",[87],278,[27],[2401],{"trials":2431,"activeCount":97},[],{"trials":2433,"activeCount":97},[],{"trials":2435,"activeCount":97},[],{"intervention":2437,"totalTrials":229,"cells":2438},"Lu AA24493",{"EARLY_PHASE1":2439,"PHASE1":2441,"PHASE2":2458,"PHASE3":2468,"PHASE4":2470,"NA":2472},{"trials":2440,"activeCount":97},[],{"trials":2442,"activeCount":97},[2443,2452],{"nctId":2444,"briefTitle":2445,"status":103,"phases":2446,"primaryCompletion":2447,"completion":802,"start":2448,"enrollment":494,"conditions":2449,"interventions":2451},"NCT00870844","Safety and Pharmacokinetic Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke",[86],"2010-12","2009-05",[2450],"Acute Ischemic Stroke",[2437],{"nctId":2453,"briefTitle":2454,"status":103,"phases":2455,"primaryCompletion":1313,"completion":630,"start":725,"enrollment":93,"conditions":2456,"interventions":2457},"NCT00756249","Safety Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke",[86],[2450],[2437],{"trials":2459,"activeCount":97},[2460],{"nctId":2461,"briefTitle":2462,"status":103,"phases":2463,"primaryCompletion":802,"completion":803,"start":1311,"enrollment":2464,"conditions":2465,"interventions":2467},"NCT01016366","Safety Study of Carbamylated Erythropoietin to Treat Patients With the Neurodegenerative Disorder Friedreich's Ataxia",[87],36,[2466],"Friedreich's Ataxia",[2437],{"trials":2469,"activeCount":97},[],{"trials":2471,"activeCount":97},[],{"trials":2473,"activeCount":97},[],{"intervention":1686,"totalTrials":12,"cells":2475},{"EARLY_PHASE1":2476,"PHASE1":2478,"PHASE2":2480,"PHASE3":2495,"PHASE4":2497,"NA":2499},{"trials":2477,"activeCount":97},[],{"trials":2479,"activeCount":97},[],{"trials":2481,"activeCount":97},[2482,2486],{"nctId":1680,"briefTitle":1681,"status":252,"phases":2483,"primaryCompletion":631,"completion":610,"start":1313,"enrollment":1683,"conditions":2484,"interventions":2485},[87],[18],[1686,1671],{"nctId":2487,"briefTitle":2488,"status":252,"phases":2489,"primaryCompletion":631,"completion":1312,"start":1558,"enrollment":2490,"conditions":2491,"interventions":2493},"NCT00622245","Efficacy and Safety of Lu AA34893 in Patients With Bipolar Depression",[87],166,[2492],"Depression in Patients With Bipolar Disorder",[1686,2494],"Quetiapine fumarate",{"trials":2496,"activeCount":97},[],{"trials":2498,"activeCount":97},[],{"trials":2500,"activeCount":97},[],{"intervention":1594,"totalTrials":12,"cells":2502},{"EARLY_PHASE1":2503,"PHASE1":2505,"PHASE2":2511,"PHASE3":2517,"PHASE4":2519,"NA":2521},{"trials":2504,"activeCount":97},[],{"trials":2506,"activeCount":97},[2507],{"nctId":1575,"briefTitle":1576,"status":103,"phases":2508,"primaryCompletion":1578,"start":1453,"enrollment":257,"conditions":2509,"interventions":2510},[86],[1580],[1568,1582,1583],{"trials":2512,"activeCount":97},[2513],{"nctId":1587,"briefTitle":1588,"status":103,"phases":2514,"primaryCompletion":1061,"completion":1061,"start":1225,"enrollment":1373,"conditions":2515,"interventions":2516},[87],[1591],[1593,1594],{"trials":2518,"activeCount":97},[],{"trials":2520,"activeCount":97},[],{"trials":2522,"activeCount":97},[],{"intervention":1366,"totalTrials":264,"cells":2524},{"EARLY_PHASE1":2525,"PHASE1":2527,"PHASE2":2529,"PHASE3":2535,"PHASE4":2537,"NA":2539},{"trials":2526,"activeCount":97},[],{"trials":2528,"activeCount":97},[],{"trials":2530,"activeCount":97},[2531],{"nctId":1357,"briefTitle":1358,"status":252,"phases":2532,"primaryCompletion":1360,"completion":1361,"start":630,"enrollment":1362,"conditions":2533,"interventions":2534},[87],[1364],[1366,690],{"trials":2536,"activeCount":97},[],{"trials":2538,"activeCount":97},[],{"trials":2540,"activeCount":97},[],{"intervention":2494,"totalTrials":264,"cells":2542},{"EARLY_PHASE1":2543,"PHASE1":2545,"PHASE2":2547,"PHASE3":2553,"PHASE4":2555,"NA":2557},{"trials":2544,"activeCount":97},[],{"trials":2546,"activeCount":97},[],{"trials":2548,"activeCount":97},[2549],{"nctId":2487,"briefTitle":2488,"status":252,"phases":2550,"primaryCompletion":631,"completion":1312,"start":1558,"enrollment":2490,"conditions":2551,"interventions":2552},[87],[2492],[1686,2494],{"trials":2554,"activeCount":97},[],{"trials":2556,"activeCount":97},[],{"trials":2558,"activeCount":97},[],{"intervention":729,"totalTrials":264,"cells":2560},{"EARLY_PHASE1":2561,"PHASE1":2563,"PHASE2":2565,"PHASE3":2571,"PHASE4":2573,"NA":2575},{"trials":2562,"activeCount":97},[],{"trials":2564,"activeCount":97},[],{"trials":2566,"activeCount":97},[2567],{"nctId":721,"briefTitle":722,"status":103,"phases":2568,"primaryCompletion":724,"completion":611,"start":725,"enrollment":726,"conditions":2569,"interventions":2570},[87],[18],[729,711],{"trials":2572,"activeCount":97},[],{"trials":2574,"activeCount":97},[],{"trials":2576,"activeCount":97},[],{"intervention":2578,"totalTrials":264,"cells":2579},"MK0928, gaboxadol \u002F Duration of Treatment 3 Weeks",{"EARLY_PHASE1":2580,"PHASE1":2582,"PHASE2":2584,"PHASE3":2593,"PHASE4":2595,"NA":2597},{"trials":2581,"activeCount":97},[],{"trials":2583,"activeCount":97},[],{"trials":2585,"activeCount":97},[2586],{"nctId":2587,"briefTitle":2588,"status":103,"phases":2589,"completion":695,"start":1161,"enrollment":2590,"conditions":2591,"interventions":2592},"NCT00266344","MK0928 Study in Adult Patients With Primary Insomnia (0928-040)(COMPLETED)",[87],520,[30],[2578],{"trials":2594,"activeCount":97},[],{"trials":2596,"activeCount":97},[],{"trials":2598,"activeCount":97},[],{"intervention":2600,"totalTrials":264,"cells":2601},"Vortioxetine infusion 25 mg",{"EARLY_PHASE1":2602,"PHASE1":2604,"PHASE2":2606,"PHASE3":2619,"PHASE4":2621,"NA":2623},{"trials":2603,"activeCount":97},[],{"trials":2605,"activeCount":97},[],{"trials":2607,"activeCount":97},[2608],{"nctId":2609,"briefTitle":2610,"status":103,"phases":2611,"primaryCompletion":2612,"completion":2613,"start":2614,"enrollment":2615,"conditions":2616,"interventions":2617},"NCT03766867","Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With Depression",[87],"2019-07-31","2019-08-28","2018-12-03",80,[18],[2600,2618],"Vortioxetine tablets 10 mg\u002Fday",{"trials":2620,"activeCount":97},[],{"trials":2622,"activeCount":97},[],{"trials":2624,"activeCount":97},[],{"intervention":2618,"totalTrials":264,"cells":2626},{"EARLY_PHASE1":2627,"PHASE1":2629,"PHASE2":2631,"PHASE3":2637,"PHASE4":2639,"NA":2641},{"trials":2628,"activeCount":97},[],{"trials":2630,"activeCount":97},[],{"trials":2632,"activeCount":97},[2633],{"nctId":2609,"briefTitle":2610,"status":103,"phases":2634,"primaryCompletion":2612,"completion":2613,"start":2614,"enrollment":2615,"conditions":2635,"interventions":2636},[87],[18],[2600,2618],{"trials":2638,"activeCount":97},[],{"trials":2640,"activeCount":97},[],{"trials":2642,"activeCount":97},[],{"intervention":2644,"totalTrials":264,"cells":2645},"Zicronapine open-label lead-in 10 mg daily",{"EARLY_PHASE1":2646,"PHASE1":2648,"PHASE2":2650,"PHASE3":2665,"PHASE4":2667,"NA":2669},{"trials":2647,"activeCount":97},[],{"trials":2649,"activeCount":97},[],{"trials":2651,"activeCount":97},[2652],{"nctId":2653,"briefTitle":2654,"status":103,"phases":2655,"primaryCompletion":2656,"start":2657,"enrollment":2658,"conditions":2659,"interventions":2660},"NCT01377233","Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With Schizophrenia",[87],"2012-02","2011-07",46,[21],[2644,2661,2662,2663,2664],"Zicronapine 10 mg daily","Zicronapine 20 mg once weekly","Zicronapine 30 mg once weekly","Zicronapine 45 mg once weekly",{"trials":2666,"activeCount":97},[],{"trials":2668,"activeCount":97},[],{"trials":2670,"activeCount":97},[],{"intervention":2661,"totalTrials":264,"cells":2672},{"EARLY_PHASE1":2673,"PHASE1":2675,"PHASE2":2677,"PHASE3":2683,"PHASE4":2685,"NA":2687},{"trials":2674,"activeCount":97},[],{"trials":2676,"activeCount":97},[],{"trials":2678,"activeCount":97},[2679],{"nctId":2653,"briefTitle":2654,"status":103,"phases":2680,"primaryCompletion":2656,"start":2657,"enrollment":2658,"conditions":2681,"interventions":2682},[87],[21],[2644,2661,2662,2663,2664],{"trials":2684,"activeCount":97},[],{"trials":2686,"activeCount":97},[],{"trials":2688,"activeCount":97},[],{"intervention":2662,"totalTrials":264,"cells":2690},{"EARLY_PHASE1":2691,"PHASE1":2693,"PHASE2":2695,"PHASE3":2701,"PHASE4":2703,"NA":2705},{"trials":2692,"activeCount":97},[],{"trials":2694,"activeCount":97},[],{"trials":2696,"activeCount":97},[2697],{"nctId":2653,"briefTitle":2654,"status":103,"phases":2698,"primaryCompletion":2656,"start":2657,"enrollment":2658,"conditions":2699,"interventions":2700},[87],[21],[2644,2661,2662,2663,2664],{"trials":2702,"activeCount":97},[],{"trials":2704,"activeCount":97},[],{"trials":2706,"activeCount":97},[],{"intervention":2663,"totalTrials":264,"cells":2708},{"EARLY_PHASE1":2709,"PHASE1":2711,"PHASE2":2713,"PHASE3":2719,"PHASE4":2721,"NA":2723},{"trials":2710,"activeCount":97},[],{"trials":2712,"activeCount":97},[],{"trials":2714,"activeCount":97},[2715],{"nctId":2653,"briefTitle":2654,"status":103,"phases":2716,"primaryCompletion":2656,"start":2657,"enrollment":2658,"conditions":2717,"interventions":2718},[87],[21],[2644,2661,2662,2663,2664],{"trials":2720,"activeCount":97},[],{"trials":2722,"activeCount":97},[],{"trials":2724,"activeCount":97},[],{"intervention":2664,"totalTrials":264,"cells":2726},{"EARLY_PHASE1":2727,"PHASE1":2729,"PHASE2":2731,"PHASE3":2737,"PHASE4":2739,"NA":2741},{"trials":2728,"activeCount":97},[],{"trials":2730,"activeCount":97},[],{"trials":2732,"activeCount":97},[2733],{"nctId":2653,"briefTitle":2654,"status":103,"phases":2734,"primaryCompletion":2656,"start":2657,"enrollment":2658,"conditions":2735,"interventions":2736},[87],[21],[2644,2661,2662,2663,2664],{"trials":2738,"activeCount":97},[],{"trials":2740,"activeCount":97},[],{"trials":2742,"activeCount":97},[],{"intervention":2744,"totalTrials":264,"cells":2745},"MK0928, gaboxadol \u002F Duration of Treatment: 6 days for treatment periods",{"EARLY_PHASE1":2746,"PHASE1":2748,"PHASE2":2750,"PHASE3":2759,"PHASE4":2761,"NA":2763},{"trials":2747,"activeCount":97},[],{"trials":2749,"activeCount":97},[],{"trials":2751,"activeCount":97},[2752],{"nctId":2753,"briefTitle":2754,"status":252,"phases":2755,"primaryCompletion":657,"start":1161,"enrollment":2756,"conditions":2757,"interventions":2758},"NCT00266357","Sleep Laboratory Study of MK0928 in Adult Patients With Primary Insomnia (0928-041)(TERMINATED)",[87],50,[30],[2744],{"trials":2760,"activeCount":97},[],{"trials":2762,"activeCount":97},[],{"trials":2764,"activeCount":97},[],{"intervention":2766,"totalTrials":264,"cells":2767},"Escitalopram placebo",{"EARLY_PHASE1":2768,"PHASE1":2770,"PHASE2":2772,"PHASE3":2785,"PHASE4":2787,"NA":2789},{"trials":2769,"activeCount":97},[],{"trials":2771,"activeCount":97},[],{"trials":2773,"activeCount":97},[2774],{"nctId":2775,"briefTitle":2776,"status":103,"phases":2777,"primaryCompletion":847,"completion":753,"start":2419,"enrollment":2778,"conditions":2779,"interventions":2780},"NCT00807248","Short-term Study of Combination Treatment of Escitalopram and Gaboxadol in Major Depressive Disorder",[87],490,[18],[2766,2781,2782,2783,2784],"Gaboxadol placebo","Escitalopram 20 mg","Gaboxadol 5 mg","Gaboxadol 10 mg",{"trials":2786,"activeCount":97},[],{"trials":2788,"activeCount":97},[],{"trials":2790,"activeCount":97},[],{"intervention":2781,"totalTrials":264,"cells":2792},{"EARLY_PHASE1":2793,"PHASE1":2795,"PHASE2":2797,"PHASE3":2803,"PHASE4":2805,"NA":2807},{"trials":2794,"activeCount":97},[],{"trials":2796,"activeCount":97},[],{"trials":2798,"activeCount":97},[2799],{"nctId":2775,"briefTitle":2776,"status":103,"phases":2800,"primaryCompletion":847,"completion":753,"start":2419,"enrollment":2778,"conditions":2801,"interventions":2802},[87],[18],[2766,2781,2782,2783,2784],{"trials":2804,"activeCount":97},[],{"trials":2806,"activeCount":97},[],{"trials":2808,"activeCount":97},[],{"intervention":2782,"totalTrials":264,"cells":2810},{"EARLY_PHASE1":2811,"PHASE1":2813,"PHASE2":2815,"PHASE3":2821,"PHASE4":2823,"NA":2825},{"trials":2812,"activeCount":97},[],{"trials":2814,"activeCount":97},[],{"trials":2816,"activeCount":97},[2817],{"nctId":2775,"briefTitle":2776,"status":103,"phases":2818,"primaryCompletion":847,"completion":753,"start":2419,"enrollment":2778,"conditions":2819,"interventions":2820},[87],[18],[2766,2781,2782,2783,2784],{"trials":2822,"activeCount":97},[],{"trials":2824,"activeCount":97},[],{"trials":2826,"activeCount":97},[],{"intervention":2783,"totalTrials":264,"cells":2828},{"EARLY_PHASE1":2829,"PHASE1":2831,"PHASE2":2833,"PHASE3":2839,"PHASE4":2841,"NA":2843},{"trials":2830,"activeCount":97},[],{"trials":2832,"activeCount":97},[],{"trials":2834,"activeCount":97},[2835],{"nctId":2775,"briefTitle":2776,"status":103,"phases":2836,"primaryCompletion":847,"completion":753,"start":2419,"enrollment":2778,"conditions":2837,"interventions":2838},[87],[18],[2766,2781,2782,2783,2784],{"trials":2840,"activeCount":97},[],{"trials":2842,"activeCount":97},[],{"trials":2844,"activeCount":97},[],{"intervention":2784,"totalTrials":264,"cells":2846},{"EARLY_PHASE1":2847,"PHASE1":2849,"PHASE2":2851,"PHASE3":2857,"PHASE4":2859,"NA":2861},{"trials":2848,"activeCount":97},[],{"trials":2850,"activeCount":97},[],{"trials":2852,"activeCount":97},[2853],{"nctId":2775,"briefTitle":2776,"status":103,"phases":2854,"primaryCompletion":847,"completion":753,"start":2419,"enrollment":2778,"conditions":2855,"interventions":2856},[87],[18],[2766,2781,2782,2783,2784],{"trials":2858,"activeCount":97},[],{"trials":2860,"activeCount":97},[],{"trials":2862,"activeCount":97},[],{"intervention":2864,"totalTrials":264,"cells":2865},"Venlafaxine XL",{"EARLY_PHASE1":2866,"PHASE1":2868,"PHASE2":2870,"PHASE3":2882,"PHASE4":2884,"NA":2886},{"trials":2867,"activeCount":97},[],{"trials":2869,"activeCount":97},[],{"trials":2871,"activeCount":97},[2872],{"nctId":2873,"briefTitle":2874,"status":103,"phases":2875,"primaryCompletion":2876,"completion":2877,"start":2878,"enrollment":2879,"conditions":2880,"interventions":2881},"NCT00839423","Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults",[87],"2007-08","2007-09","2006-08",426,[18],[739,2864],{"trials":2883,"activeCount":97},[],{"trials":2885,"activeCount":97},[],{"trials":2887,"activeCount":97},[],{"intervention":2889,"totalTrials":28,"cells":2890},"Lu AG06466",{"EARLY_PHASE1":2891,"PHASE1":2893,"PHASE2":2982,"PHASE3":2984,"PHASE4":2986,"NA":2988},{"trials":2892,"activeCount":97},[],{"trials":2894,"activeCount":97},[2895,2905,2913,2922,2931,2940,2948,2956,2965,2974],{"nctId":2896,"briefTitle":2897,"status":252,"phases":2898,"primaryCompletion":454,"completion":2899,"start":2900,"enrollment":2901,"conditions":2902,"interventions":2904},"NCT04990219","A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis",[86],"2023-01-31","2021-09-27",37,[2903],"Multiple Sclerosis",[2889],{"nctId":2906,"briefTitle":2907,"status":103,"phases":2908,"primaryCompletion":2909,"completion":2909,"start":2910,"enrollment":1683,"conditions":2911,"interventions":2912},"NCT04597450","Lu AG06466 in Participants With Post Traumatic Stress Disorder (PTSD)",[86],"2023-02-13","2020-09-30",[1267],[2889],{"nctId":2914,"briefTitle":2915,"status":103,"phases":2916,"primaryCompletion":2917,"completion":2918,"start":2919,"enrollment":11,"conditions":2920,"interventions":2921},"NCT05219838","Binding and Effects of Lu AG06466 in the Brain of Healthy Men",[86],"2022-08-18","2022-08-29","2022-01-18",[32],[2889],{"nctId":2923,"briefTitle":2924,"status":252,"phases":2925,"primaryCompletion":2926,"completion":2926,"start":2927,"enrollment":264,"conditions":2928,"interventions":2930},"NCT05081518","A Study of Lu AG06466 in Participants With Treatment Resistant Focal Epilepsy",[86],"2022-04-14","2021-09-29",[2929],"Focal Epilepsy",[2889],{"nctId":2932,"briefTitle":2933,"status":252,"phases":2934,"primaryCompletion":2935,"completion":2935,"start":2936,"enrollment":229,"conditions":2937,"interventions":2939},"NCT04974359","A Study to Evaluate Lu AG06466 in Participants With Fibromyalgia",[86],"2022-01-26","2021-06-24",[2938],"Fibromyalgia",[2889],{"nctId":2941,"briefTitle":2942,"status":103,"phases":2943,"primaryCompletion":2944,"completion":2944,"start":2945,"enrollment":93,"conditions":2946,"interventions":2947},"NCT04405323","Study That Evaluates the Effect of CYP3A4 Inhibition on Lu AG06466 in Healthy Men and Women",[86],"2020-07-28","2020-05-20",[15],[2889,1034],{"nctId":2949,"briefTitle":2950,"status":103,"phases":2951,"primaryCompletion":2952,"completion":2952,"start":2953,"enrollment":25,"conditions":2954,"interventions":2955},"NCT04713254","Drug Drug Interaction Study With Lu AG06466 in Young Healthy Men",[86],"2021-04-09","2020-12-08",[15],[2889],{"nctId":2957,"briefTitle":2958,"status":103,"phases":2959,"primaryCompletion":2960,"completion":2961,"start":2962,"enrollment":93,"conditions":2963,"interventions":2964},"NCT04419636","Binding of Lu AG06466 in the Brain in Healthy Men",[86],"2021-02-09","2021-02-16","2020-05-29",[15],[2889],{"nctId":2966,"briefTitle":2967,"status":103,"phases":2968,"primaryCompletion":2969,"completion":2969,"start":2970,"enrollment":93,"conditions":2971,"interventions":2972},"NCT05028673","A Study to Evaluate a New Tablet Formulation of Lu AG06466 in Healthy Participants",[86],"2021-12-29","2021-08-23",[15],[2889,2889,2973],"Antacid",{"nctId":2975,"briefTitle":2976,"status":252,"phases":2977,"primaryCompletion":2969,"completion":2969,"start":2978,"enrollment":494,"conditions":2979,"interventions":2981},"NCT05177029","Safety and Tolerability Study of Lu AG06466 in Healthy Young Japanese and Caucasian Participants",[86],"2021-11-26",[2980],"Healthy Volunteers",[2889],{"trials":2983,"activeCount":97},[],{"trials":2985,"activeCount":97},[],{"trials":2987,"activeCount":97},[],{"trials":2989,"activeCount":97},[],{"intervention":1034,"totalTrials":773,"cells":2991},{"EARLY_PHASE1":2992,"PHASE1":2994,"PHASE2":3017,"PHASE3":3019,"PHASE4":3021,"NA":3023},{"trials":2993,"activeCount":97},[],{"trials":2995,"activeCount":97},[2996,3005,3009,3013],{"nctId":2997,"briefTitle":2998,"status":103,"phases":2999,"primaryCompletion":3000,"start":1462,"enrollment":126,"conditions":3001,"interventions":3002},"NCT02122692","Effect of Multiple Doses of Itraconazole on the Multiple Dose Pharmacokinetics of Lu AE58054 in Healthy Subjects",[86],"2014-06",[2980],[3003,3004,1034],"Lu AE58054 30 mg","Lu AE58054 30 mg + itraconazole 200 mg",{"nctId":2351,"briefTitle":2352,"status":103,"phases":3006,"primaryCompletion":1088,"start":1245,"enrollment":126,"conditions":3007,"interventions":3008},[86],[15],[2337,1034],{"nctId":2941,"briefTitle":2942,"status":103,"phases":3010,"primaryCompletion":2944,"completion":2944,"start":2945,"enrollment":93,"conditions":3011,"interventions":3012},[86],[15],[2889,1034],{"nctId":1025,"briefTitle":1026,"status":103,"phases":3014,"primaryCompletion":1028,"completion":1029,"start":1030,"enrollment":325,"conditions":3015,"interventions":3016},[86],[1032],[1007,1034,1034],{"trials":3018,"activeCount":97},[],{"trials":3020,"activeCount":97},[],{"trials":3022,"activeCount":97},[],{"trials":3024,"activeCount":97},[],{"intervention":3026,"totalTrials":229,"cells":3027},"Foliglurax",{"EARLY_PHASE1":3028,"PHASE1":3030,"PHASE2":3061,"PHASE3":3063,"PHASE4":3065,"NA":3067},{"trials":3029,"activeCount":97},[],{"trials":3031,"activeCount":97},[3032,3042,3052],{"nctId":3033,"briefTitle":3034,"status":103,"phases":3035,"primaryCompletion":3036,"completion":3036,"start":3037,"enrollment":126,"conditions":3038,"interventions":3039},"NCT04275115","Effects of Repeated Doses of Foliglurax on Drug Metabolizing Enzymes in Healthy Subjects",[86],"2020-04-03","2020-02-10",[15],[3040,3026,3041],"Drug Cocktail","midazolam iv",{"nctId":3043,"briefTitle":3044,"status":252,"phases":3045,"primaryCompletion":3046,"completion":3047,"start":3048,"enrollment":306,"conditions":3049,"interventions":3050},"NCT04175132","Binding of Foliglurax to Regions in the Brain in Healthy Participants and in Patients With Parkinson's Disease (PD)",[86],"2020-03-03","2020-03-10","2019-11-12",[15,35],[3051,3051],"foliglurax",{"nctId":3053,"briefTitle":3054,"status":103,"phases":3055,"primaryCompletion":3056,"completion":3057,"start":3058,"enrollment":306,"conditions":3059,"interventions":3060},"NCT04002895","What the Body Does to Foliglurax in Healthy Volunteers",[86],"2019-08-01","2019-08-08","2019-06-27",[15],[3026],{"trials":3062,"activeCount":97},[],{"trials":3064,"activeCount":97},[],{"trials":3066,"activeCount":97},[],{"trials":3068,"activeCount":97},[],{"intervention":3070,"totalTrials":229,"cells":3071},"Lu AG06474",{"EARLY_PHASE1":3072,"PHASE1":3074,"PHASE2":3105,"PHASE3":3107,"PHASE4":3109,"NA":3111},{"trials":3073,"activeCount":97},[],{"trials":3075,"activeCount":97},[3076,3085,3096],{"nctId":3077,"briefTitle":3078,"status":103,"phases":3079,"primaryCompletion":3080,"completion":3080,"start":3081,"enrollment":3082,"conditions":3083,"interventions":3084},"NCT05003687","Safety and Tolerability of Lu AG06474 in Healthy Young Men",[86],"2022-12-22","2021-08-04",79,[15],[3070],{"nctId":3086,"briefTitle":3087,"status":103,"phases":3088,"primaryCompletion":3089,"completion":3090,"start":3091,"enrollment":1256,"conditions":3092,"interventions":3093},"NCT06077786","A Trial Investigating the Pain-relieving Properties of Lu AG06474 in Healthy Adult Participants",[86],"2024-05-10","2024-05-17","2023-10-13",[32],[3070,3094,3095],"Ibuprofen","Pregabalin",{"nctId":3097,"briefTitle":3098,"status":252,"phases":3099,"primaryCompletion":3100,"completion":3100,"start":3101,"enrollment":3102,"conditions":3103,"interventions":3104},"NCT05943327","A Study Investigating Lu AG06474 in Healthy Young Participants",[86],"2024-07-19","2023-06-28",56,[32],[3070,3070],{"trials":3106,"activeCount":97},[],{"trials":3108,"activeCount":97},[],{"trials":3110,"activeCount":97},[],{"trials":3112,"activeCount":97},[],{"intervention":3114,"totalTrials":12,"cells":3115},"Lu AF20513",{"EARLY_PHASE1":3116,"PHASE1":3118,"PHASE2":3137,"PHASE3":3139,"PHASE4":3141,"NA":3143},{"trials":3117,"activeCount":97},[],{"trials":3119,"activeCount":97},[3120,3128],{"nctId":3121,"briefTitle":3122,"status":252,"phases":3123,"primaryCompletion":3124,"completion":3124,"start":3125,"enrollment":117,"conditions":3126,"interventions":3127},"NCT03668405","A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD)",[86],"2019-05-27","2018-06-26",[27],[3114],{"nctId":3129,"briefTitle":3130,"status":252,"phases":3131,"primaryCompletion":3058,"completion":3058,"start":3132,"enrollment":229,"conditions":3133,"interventions":3135},"NCT03819699","Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD",[86],"2018-12-12",[3134],"Alzheimer Disease",[3114,3136],"booster vaccine",{"trials":3138,"activeCount":97},[],{"trials":3140,"activeCount":97},[],{"trials":3142,"activeCount":97},[],{"trials":3144,"activeCount":97},[],{"intervention":3146,"totalTrials":12,"cells":3147},"Lu AF88434",{"EARLY_PHASE1":3148,"PHASE1":3150,"PHASE2":3172,"PHASE3":3174,"PHASE4":3176,"NA":3178},{"trials":3149,"activeCount":97},[],{"trials":3151,"activeCount":97},[3152,3163],{"nctId":3153,"briefTitle":3154,"status":103,"phases":3155,"primaryCompletion":3156,"completion":3156,"start":3157,"enrollment":3158,"conditions":3159,"interventions":3160},"NCT04082325","Study Investigating the Safety and Tolerability of Lu AF88434 in Healthy Young Men",[86],"2020-09-24","2019-07-23",68,[15],[3146,3161,3162],"Lu AF99722 14C spiked dosage","Lu AF99723 14C spiked dosage",{"nctId":3164,"briefTitle":3165,"status":103,"phases":3166,"primaryCompletion":3167,"completion":3167,"start":3168,"enrollment":11,"conditions":3169,"interventions":3170},"NCT04538014","A Study in Healthy Men to Investigate Uptake and Distribution of Lu AF88434 in the Brain",[86],"2020-10-21","2020-08-24",[15],[3146,3171],"[11C]-Lu AF88434",{"trials":3173,"activeCount":97},[],{"trials":3175,"activeCount":97},[],{"trials":3177,"activeCount":97},[],{"trials":3179,"activeCount":97},[],{"intervention":3181,"totalTrials":264,"cells":3182},"Lu AE58054 encapsulated film-coated",{"EARLY_PHASE1":3183,"PHASE1":3185,"PHASE2":3194,"PHASE3":3196,"PHASE4":3198,"NA":3200},{"trials":3184,"activeCount":97},[],{"trials":3186,"activeCount":97},[3187],{"nctId":3188,"briefTitle":3189,"status":103,"phases":3190,"primaryCompletion":1840,"start":1245,"enrollment":494,"conditions":3191,"interventions":3193},"NCT02231450","Pharmacokinetics Properties of Single Oral Dosing of Lu AE58054 in Subjects With Hepatic Impairment (Mild and Moderate) and in Healthy Subjects",[86],[3192],"Heptic Impairment",[3181],{"trials":3195,"activeCount":97},[],{"trials":3197,"activeCount":97},[],{"trials":3199,"activeCount":97},[],{"trials":3201,"activeCount":97},[],{"intervention":3203,"totalTrials":264,"cells":3204},"Lu AF87908",{"EARLY_PHASE1":3205,"PHASE1":3207,"PHASE2":3218,"PHASE3":3220,"PHASE4":3222,"NA":3224},{"trials":3206,"activeCount":97},[],{"trials":3208,"activeCount":97},[3209],{"nctId":3210,"briefTitle":3211,"status":103,"phases":3212,"primaryCompletion":3213,"completion":3213,"start":3214,"enrollment":3215,"conditions":3216,"interventions":3217},"NCT04149860","Study With Lu AF87908 in Healthy Participants and Participants With Alzheimer's Disease",[86],"2023-07-19","2019-09-27",86,[15,3134],[3203],{"trials":3219,"activeCount":97},[],{"trials":3221,"activeCount":97},[],{"trials":3223,"activeCount":97},[],{"trials":3225,"activeCount":97},[],{"intervention":3227,"totalTrials":264,"cells":3228},"Idalopirdine (Lu AE58054) 60 mg",{"EARLY_PHASE1":3229,"PHASE1":3231,"PHASE2":3241,"PHASE3":3243,"PHASE4":3245,"NA":3247},{"trials":3230,"activeCount":97},[],{"trials":3232,"activeCount":97},[3233],{"nctId":3234,"briefTitle":3235,"status":103,"phases":3236,"primaryCompletion":3237,"start":3238,"enrollment":93,"conditions":3239,"interventions":3240},"NCT02340195","Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Subjects With and Without Impaired Kidney Function",[86],"2015-09","2015-01",[3134],[3227],{"trials":3242,"activeCount":97},[],{"trials":3244,"activeCount":97},[],{"trials":3246,"activeCount":97},[],{"trials":3248,"activeCount":97},[],{"intervention":3250,"totalTrials":264,"cells":3251},"Nalmefene 18 mg",{"EARLY_PHASE1":3252,"PHASE1":3254,"PHASE2":3263,"PHASE3":3265,"PHASE4":3267,"NA":3269},{"trials":3253,"activeCount":97},[],{"trials":3255,"activeCount":97},[3256],{"nctId":3257,"briefTitle":3258,"status":103,"phases":3259,"primaryCompletion":878,"start":1291,"enrollment":257,"conditions":3260,"interventions":3262},"NCT01934166","Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment and in Healthy Subjects",[86],[3261],"Renal Impairment",[3250],{"trials":3264,"activeCount":97},[],{"trials":3266,"activeCount":97},[],{"trials":3268,"activeCount":97},[],{"trials":3270,"activeCount":97},[],{"intervention":3272,"totalTrials":264,"cells":3273},"Lu AG06479",{"EARLY_PHASE1":3274,"PHASE1":3276,"PHASE2":3287,"PHASE3":3289,"PHASE4":3291,"NA":3293},{"trials":3275,"activeCount":97},[],{"trials":3277,"activeCount":97},[3278],{"nctId":3279,"briefTitle":3280,"status":252,"phases":3281,"primaryCompletion":3282,"completion":3282,"start":3283,"enrollment":2658,"conditions":3284,"interventions":3285},"NCT04473651","Safety and Tolerability of Lu AG06479 in Healthy Young Men",[86],"2021-11-10","2020-07-09",[15],[3272,3286],"Placebos",{"trials":3288,"activeCount":97},[],{"trials":3290,"activeCount":97},[],{"trials":3292,"activeCount":97},[],{"trials":3294,"activeCount":97},[],{"intervention":3286,"totalTrials":264,"cells":3296},{"EARLY_PHASE1":3297,"PHASE1":3299,"PHASE2":3305,"PHASE3":3307,"PHASE4":3309,"NA":3311},{"trials":3298,"activeCount":97},[],{"trials":3300,"activeCount":97},[3301],{"nctId":3279,"briefTitle":3280,"status":252,"phases":3302,"primaryCompletion":3282,"completion":3282,"start":3283,"enrollment":2658,"conditions":3303,"interventions":3304},[86],[15],[3272,3286],{"trials":3306,"activeCount":97},[],{"trials":3308,"activeCount":97},[],{"trials":3310,"activeCount":97},[],{"trials":3312,"activeCount":97},[],{"intervention":328,"totalTrials":264,"cells":3314},{"EARLY_PHASE1":3315,"PHASE1":3317,"PHASE2":3323,"PHASE3":3325,"PHASE4":3327,"NA":3329},{"trials":3316,"activeCount":97},[],{"trials":3318,"activeCount":97},[3319],{"nctId":320,"briefTitle":321,"status":103,"phases":3320,"primaryCompletion":323,"completion":323,"start":324,"enrollment":325,"conditions":3321,"interventions":3322},[86],[32],[79,328,329,330],{"trials":3324,"activeCount":97},[],{"trials":3326,"activeCount":97},[],{"trials":3328,"activeCount":97},[],{"trials":3330,"activeCount":97},[],{"intervention":329,"totalTrials":264,"cells":3332},{"EARLY_PHASE1":3333,"PHASE1":3335,"PHASE2":3341,"PHASE3":3343,"PHASE4":3345,"NA":3347},{"trials":3334,"activeCount":97},[],{"trials":3336,"activeCount":97},[3337],{"nctId":320,"briefTitle":321,"status":103,"phases":3338,"primaryCompletion":323,"completion":323,"start":324,"enrollment":325,"conditions":3339,"interventions":3340},[86],[32],[79,328,329,330],{"trials":3342,"activeCount":97},[],{"trials":3344,"activeCount":97},[],{"trials":3346,"activeCount":97},[],{"trials":3348,"activeCount":97},[],{"intervention":330,"totalTrials":264,"cells":3350},{"EARLY_PHASE1":3351,"PHASE1":3353,"PHASE2":3359,"PHASE3":3361,"PHASE4":3363,"NA":3365},{"trials":3352,"activeCount":97},[],{"trials":3354,"activeCount":97},[3355],{"nctId":320,"briefTitle":321,"status":103,"phases":3356,"primaryCompletion":323,"completion":323,"start":324,"enrollment":325,"conditions":3357,"interventions":3358},[86],[32],[79,328,329,330],{"trials":3360,"activeCount":97},[],{"trials":3362,"activeCount":97},[],{"trials":3364,"activeCount":97},[],{"trials":3366,"activeCount":97},[],{"intervention":3368,"totalTrials":264,"cells":3369},"test treatment: flupentixol\u002Fmelitracen",{"EARLY_PHASE1":3370,"PHASE1":3372,"PHASE2":3384,"PHASE3":3386,"PHASE4":3388,"NA":3390},{"trials":3371,"activeCount":97},[],{"trials":3373,"activeCount":97},[3374],{"nctId":3375,"briefTitle":3376,"status":103,"phases":3377,"primaryCompletion":3378,"completion":3378,"start":3379,"enrollment":3380,"conditions":3381,"interventions":3382},"NCT03472651","Bioequivalence Study to Compare Two Formulations of Deanxit®",[86],"2018-06-28","2018-05-07",60,[15],[3368,3383],"reference treatment: flupentixol\u002Fmelitracen",{"trials":3385,"activeCount":97},[],{"trials":3387,"activeCount":97},[],{"trials":3389,"activeCount":97},[],{"trials":3391,"activeCount":97},[],{"intervention":3383,"totalTrials":264,"cells":3393},{"EARLY_PHASE1":3394,"PHASE1":3396,"PHASE2":3402,"PHASE3":3404,"PHASE4":3406,"NA":3408},{"trials":3395,"activeCount":97},[],{"trials":3397,"activeCount":97},[3398],{"nctId":3375,"briefTitle":3376,"status":103,"phases":3399,"primaryCompletion":3378,"completion":3378,"start":3379,"enrollment":3380,"conditions":3400,"interventions":3401},[86],[15],[3368,3383],{"trials":3403,"activeCount":97},[],{"trials":3405,"activeCount":97},[],{"trials":3407,"activeCount":97},[],{"trials":3409,"activeCount":97},[],{"intervention":3411,"totalTrials":264,"cells":3412},"Vortioxetine IV",{"EARLY_PHASE1":3413,"PHASE1":3415,"PHASE2":3429,"PHASE3":3431,"PHASE4":3433,"NA":3435},{"trials":3414,"activeCount":97},[],{"trials":3416,"activeCount":97},[3417],{"nctId":3418,"briefTitle":3419,"status":103,"phases":3420,"primaryCompletion":3421,"completion":3422,"start":3423,"enrollment":93,"conditions":3424,"interventions":3425},"NCT03884491","A Study Investigating Formulations of Vortioxetine Applied Under the Tongue in Healthy Subjects",[86],"2019-06-25","2019-07-22","2019-03-18",[15],[3411,3426,3427,3428],"Vortioxetine SLA","Vortioxetine SLB","Vortioxetine SLC",{"trials":3430,"activeCount":97},[],{"trials":3432,"activeCount":97},[],{"trials":3434,"activeCount":97},[],{"trials":3436,"activeCount":97},[],{"intervention":3426,"totalTrials":264,"cells":3438},{"EARLY_PHASE1":3439,"PHASE1":3441,"PHASE2":3447,"PHASE3":3449,"PHASE4":3451,"NA":3453},{"trials":3440,"activeCount":97},[],{"trials":3442,"activeCount":97},[3443],{"nctId":3418,"briefTitle":3419,"status":103,"phases":3444,"primaryCompletion":3421,"completion":3422,"start":3423,"enrollment":93,"conditions":3445,"interventions":3446},[86],[15],[3411,3426,3427,3428],{"trials":3448,"activeCount":97},[],{"trials":3450,"activeCount":97},[],{"trials":3452,"activeCount":97},[],{"trials":3454,"activeCount":97},[],{"intervention":3427,"totalTrials":264,"cells":3456},{"EARLY_PHASE1":3457,"PHASE1":3459,"PHASE2":3465,"PHASE3":3467,"PHASE4":3469,"NA":3471},{"trials":3458,"activeCount":97},[],{"trials":3460,"activeCount":97},[3461],{"nctId":3418,"briefTitle":3419,"status":103,"phases":3462,"primaryCompletion":3421,"completion":3422,"start":3423,"enrollment":93,"conditions":3463,"interventions":3464},[86],[15],[3411,3426,3427,3428],{"trials":3466,"activeCount":97},[],{"trials":3468,"activeCount":97},[],{"trials":3470,"activeCount":97},[],{"trials":3472,"activeCount":97},[],{"intervention":3428,"totalTrials":264,"cells":3474},{"EARLY_PHASE1":3475,"PHASE1":3477,"PHASE2":3483,"PHASE3":3485,"PHASE4":3487,"NA":3489},{"trials":3476,"activeCount":97},[],{"trials":3478,"activeCount":97},[3479],{"nctId":3418,"briefTitle":3419,"status":103,"phases":3480,"primaryCompletion":3421,"completion":3422,"start":3423,"enrollment":93,"conditions":3481,"interventions":3482},[86],[15],[3411,3426,3427,3428],{"trials":3484,"activeCount":97},[],{"trials":3486,"activeCount":97},[],{"trials":3488,"activeCount":97},[],{"trials":3490,"activeCount":97},[],{"intervention":3492,"totalTrials":264,"cells":3493},"Lu AF95245",{"EARLY_PHASE1":3494,"PHASE1":3496,"PHASE2":3508,"PHASE3":3510,"PHASE4":3512,"NA":3514},{"trials":3495,"activeCount":97},[],{"trials":3497,"activeCount":97},[3498],{"nctId":3499,"briefTitle":3500,"status":252,"phases":3501,"primaryCompletion":3502,"completion":3503,"start":3504,"enrollment":117,"conditions":3505,"interventions":3506},"NCT04199585","Safety and Tolerability of Lu AF95245 in Healthy Young Men",[86],"2020-02-16","2020-02-19","2019-12-10",[15],[3492,3507],"Lu AF95245 14C radiolabelled spiked dosage",{"trials":3509,"activeCount":97},[],{"trials":3511,"activeCount":97},[],{"trials":3513,"activeCount":97},[],{"trials":3515,"activeCount":97},[],{"intervention":3507,"totalTrials":264,"cells":3517},{"EARLY_PHASE1":3518,"PHASE1":3520,"PHASE2":3526,"PHASE3":3528,"PHASE4":3530,"NA":3532},{"trials":3519,"activeCount":97},[],{"trials":3521,"activeCount":97},[3522],{"nctId":3499,"briefTitle":3500,"status":252,"phases":3523,"primaryCompletion":3502,"completion":3503,"start":3504,"enrollment":117,"conditions":3524,"interventions":3525},[86],[15],[3492,3507],{"trials":3527,"activeCount":97},[],{"trials":3529,"activeCount":97},[],{"trials":3531,"activeCount":97},[],{"trials":3533,"activeCount":97},[],{"intervention":3535,"totalTrials":264,"cells":3536},"0.04 mg Lu AE04621",{"EARLY_PHASE1":3537,"PHASE1":3539,"PHASE2":3555,"PHASE3":3557,"PHASE4":3559,"NA":3561},{"trials":3538,"activeCount":97},[],{"trials":3540,"activeCount":97},[3541],{"nctId":3542,"briefTitle":3543,"status":103,"phases":3544,"primaryCompletion":1452,"completion":1452,"start":3545,"enrollment":25,"conditions":3546,"interventions":3547},"NCT02649608","An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients",[86],"2016-01",[35],[3535,3548,3549,3550,3551,3552,3553,3554],"0.08 mg Lu AE04621","0.2 mg Lu AE04621","0.4 mg Lu AE04621","0.6 mg Lu AE04621","0.8 mg Lu AE04621","1.0 mg Lu AE04621","1.2 mg Lu AE04621",{"trials":3556,"activeCount":97},[],{"trials":3558,"activeCount":97},[],{"trials":3560,"activeCount":97},[],{"trials":3562,"activeCount":97},[],{"intervention":3548,"totalTrials":264,"cells":3564},{"EARLY_PHASE1":3565,"PHASE1":3567,"PHASE2":3573,"PHASE3":3575,"PHASE4":3577,"NA":3579},{"trials":3566,"activeCount":97},[],{"trials":3568,"activeCount":97},[3569],{"nctId":3542,"briefTitle":3543,"status":103,"phases":3570,"primaryCompletion":1452,"completion":1452,"start":3545,"enrollment":25,"conditions":3571,"interventions":3572},[86],[35],[3535,3548,3549,3550,3551,3552,3553,3554],{"trials":3574,"activeCount":97},[],{"trials":3576,"activeCount":97},[],{"trials":3578,"activeCount":97},[],{"trials":3580,"activeCount":97},[],{"intervention":3549,"totalTrials":264,"cells":3582},{"EARLY_PHASE1":3583,"PHASE1":3585,"PHASE2":3591,"PHASE3":3593,"PHASE4":3595,"NA":3597},{"trials":3584,"activeCount":97},[],{"trials":3586,"activeCount":97},[3587],{"nctId":3542,"briefTitle":3543,"status":103,"phases":3588,"primaryCompletion":1452,"completion":1452,"start":3545,"enrollment":25,"conditions":3589,"interventions":3590},[86],[35],[3535,3548,3549,3550,3551,3552,3553,3554],{"trials":3592,"activeCount":97},[],{"trials":3594,"activeCount":97},[],{"trials":3596,"activeCount":97},[],{"trials":3598,"activeCount":97},[],{"intervention":3550,"totalTrials":264,"cells":3600},{"EARLY_PHASE1":3601,"PHASE1":3603,"PHASE2":3609,"PHASE3":3611,"PHASE4":3613,"NA":3615},{"trials":3602,"activeCount":97},[],{"trials":3604,"activeCount":97},[3605],{"nctId":3542,"briefTitle":3543,"status":103,"phases":3606,"primaryCompletion":1452,"completion":1452,"start":3545,"enrollment":25,"conditions":3607,"interventions":3608},[86],[35],[3535,3548,3549,3550,3551,3552,3553,3554],{"trials":3610,"activeCount":97},[],{"trials":3612,"activeCount":97},[],{"trials":3614,"activeCount":97},[],{"trials":3616,"activeCount":97},[],{"intervention":3551,"totalTrials":264,"cells":3618},{"EARLY_PHASE1":3619,"PHASE1":3621,"PHASE2":3627,"PHASE3":3629,"PHASE4":3631,"NA":3633},{"trials":3620,"activeCount":97},[],{"trials":3622,"activeCount":97},[3623],{"nctId":3542,"briefTitle":3543,"status":103,"phases":3624,"primaryCompletion":1452,"completion":1452,"start":3545,"enrollment":25,"conditions":3625,"interventions":3626},[86],[35],[3535,3548,3549,3550,3551,3552,3553,3554],{"trials":3628,"activeCount":97},[],{"trials":3630,"activeCount":97},[],{"trials":3632,"activeCount":97},[],{"trials":3634,"activeCount":97},[],{"intervention":3552,"totalTrials":264,"cells":3636},{"EARLY_PHASE1":3637,"PHASE1":3639,"PHASE2":3645,"PHASE3":3647,"PHASE4":3649,"NA":3651},{"trials":3638,"activeCount":97},[],{"trials":3640,"activeCount":97},[3641],{"nctId":3542,"briefTitle":3543,"status":103,"phases":3642,"primaryCompletion":1452,"completion":1452,"start":3545,"enrollment":25,"conditions":3643,"interventions":3644},[86],[35],[3535,3548,3549,3550,3551,3552,3553,3554],{"trials":3646,"activeCount":97},[],{"trials":3648,"activeCount":97},[],{"trials":3650,"activeCount":97},[],{"trials":3652,"activeCount":97},[],{"intervention":3553,"totalTrials":264,"cells":3654},{"EARLY_PHASE1":3655,"PHASE1":3657,"PHASE2":3663,"PHASE3":3665,"PHASE4":3667,"NA":3669},{"trials":3656,"activeCount":97},[],{"trials":3658,"activeCount":97},[3659],{"nctId":3542,"briefTitle":3543,"status":103,"phases":3660,"primaryCompletion":1452,"completion":1452,"start":3545,"enrollment":25,"conditions":3661,"interventions":3662},[86],[35],[3535,3548,3549,3550,3551,3552,3553,3554],{"trials":3664,"activeCount":97},[],{"trials":3666,"activeCount":97},[],{"trials":3668,"activeCount":97},[],{"trials":3670,"activeCount":97},[],{"intervention":3554,"totalTrials":264,"cells":3672},{"EARLY_PHASE1":3673,"PHASE1":3675,"PHASE2":3681,"PHASE3":3683,"PHASE4":3685,"NA":3687},{"trials":3674,"activeCount":97},[],{"trials":3676,"activeCount":97},[3677],{"nctId":3542,"briefTitle":3543,"status":103,"phases":3678,"primaryCompletion":1452,"completion":1452,"start":3545,"enrollment":25,"conditions":3679,"interventions":3680},[86],[35],[3535,3548,3549,3550,3551,3552,3553,3554],{"trials":3682,"activeCount":97},[],{"trials":3684,"activeCount":97},[],{"trials":3686,"activeCount":97},[],{"trials":3688,"activeCount":97},[],{"intervention":3040,"totalTrials":264,"cells":3690},{"EARLY_PHASE1":3691,"PHASE1":3693,"PHASE2":3699,"PHASE3":3701,"PHASE4":3703,"NA":3705},{"trials":3692,"activeCount":97},[],{"trials":3694,"activeCount":97},[3695],{"nctId":3033,"briefTitle":3034,"status":103,"phases":3696,"primaryCompletion":3036,"completion":3036,"start":3037,"enrollment":126,"conditions":3697,"interventions":3698},[86],[15],[3040,3026,3041],{"trials":3700,"activeCount":97},[],{"trials":3702,"activeCount":97},[],{"trials":3704,"activeCount":97},[],{"trials":3706,"activeCount":97},[],{"intervention":3041,"totalTrials":264,"cells":3708},{"EARLY_PHASE1":3709,"PHASE1":3711,"PHASE2":3717,"PHASE3":3719,"PHASE4":3721,"NA":3723},{"trials":3710,"activeCount":97},[],{"trials":3712,"activeCount":97},[3713],{"nctId":3033,"briefTitle":3034,"status":103,"phases":3714,"primaryCompletion":3036,"completion":3036,"start":3037,"enrollment":126,"conditions":3715,"interventions":3716},[86],[15],[3040,3026,3041],{"trials":3718,"activeCount":97},[],{"trials":3720,"activeCount":97},[],{"trials":3722,"activeCount":97},[],{"trials":3724,"activeCount":97},[],{"intervention":3726,"totalTrials":264,"cells":3727},"Lu AF20513, low dose",{"EARLY_PHASE1":3728,"PHASE1":3730,"PHASE2":3742,"PHASE3":3744,"PHASE4":3746,"NA":3748},{"trials":3729,"activeCount":97},[],{"trials":3731,"activeCount":97},[3732],{"nctId":3733,"briefTitle":3734,"status":252,"phases":3735,"primaryCompletion":3736,"completion":3736,"start":1840,"enrollment":2756,"conditions":3737,"interventions":3738},"NCT02388152","Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease",[86],"2019-07-04",[3134],[3726,3739,3740,3741],"Lu AF20513, medium dose","Lu AF20513, high dose","Lu AF20513, double high dose",{"trials":3743,"activeCount":97},[],{"trials":3745,"activeCount":97},[],{"trials":3747,"activeCount":97},[],{"trials":3749,"activeCount":97},[],{"intervention":3739,"totalTrials":264,"cells":3751},{"EARLY_PHASE1":3752,"PHASE1":3754,"PHASE2":3760,"PHASE3":3762,"PHASE4":3764,"NA":3766},{"trials":3753,"activeCount":97},[],{"trials":3755,"activeCount":97},[3756],{"nctId":3733,"briefTitle":3734,"status":252,"phases":3757,"primaryCompletion":3736,"completion":3736,"start":1840,"enrollment":2756,"conditions":3758,"interventions":3759},[86],[3134],[3726,3739,3740,3741],{"trials":3761,"activeCount":97},[],{"trials":3763,"activeCount":97},[],{"trials":3765,"activeCount":97},[],{"trials":3767,"activeCount":97},[],{"intervention":3740,"totalTrials":264,"cells":3769},{"EARLY_PHASE1":3770,"PHASE1":3772,"PHASE2":3778,"PHASE3":3780,"PHASE4":3782,"NA":3784},{"trials":3771,"activeCount":97},[],{"trials":3773,"activeCount":97},[3774],{"nctId":3733,"briefTitle":3734,"status":252,"phases":3775,"primaryCompletion":3736,"completion":3736,"start":1840,"enrollment":2756,"conditions":3776,"interventions":3777},[86],[3134],[3726,3739,3740,3741],{"trials":3779,"activeCount":97},[],{"trials":3781,"activeCount":97},[],{"trials":3783,"activeCount":97},[],{"trials":3785,"activeCount":97},[],{"intervention":3741,"totalTrials":264,"cells":3787},{"EARLY_PHASE1":3788,"PHASE1":3790,"PHASE2":3796,"PHASE3":3798,"PHASE4":3800,"NA":3802},{"trials":3789,"activeCount":97},[],{"trials":3791,"activeCount":97},[3792],{"nctId":3733,"briefTitle":3734,"status":252,"phases":3793,"primaryCompletion":3736,"completion":3736,"start":1840,"enrollment":2756,"conditions":3794,"interventions":3795},[86],[3134],[3726,3739,3740,3741],{"trials":3797,"activeCount":97},[],{"trials":3799,"activeCount":97},[],{"trials":3801,"activeCount":97},[],{"trials":3803,"activeCount":97},[],{"intervention":3805,"totalTrials":264,"cells":3806},"[ethyl-1-14C]-idalopirdine",{"EARLY_PHASE1":3807,"PHASE1":3809,"PHASE2":3820,"PHASE3":3822,"PHASE4":3824,"NA":3826},{"trials":3808,"activeCount":97},[],{"trials":3810,"activeCount":97},[3811],{"nctId":3812,"briefTitle":3813,"status":103,"phases":3814,"primaryCompletion":3815,"completion":3815,"start":3816,"enrollment":306,"conditions":3817,"interventions":3818},"NCT02415907","Investigating the Absorption, Metabolism and Excretion (AME) of Idalopirdine",[86],"2015-06","2015-04",[15],[3805,3819],"[benzyl-7-14C]-idalopirdine",{"trials":3821,"activeCount":97},[],{"trials":3823,"activeCount":97},[],{"trials":3825,"activeCount":97},[],{"trials":3827,"activeCount":97},[],{"intervention":3819,"totalTrials":264,"cells":3829},{"EARLY_PHASE1":3830,"PHASE1":3832,"PHASE2":3838,"PHASE3":3840,"PHASE4":3842,"NA":3844},{"trials":3831,"activeCount":97},[],{"trials":3833,"activeCount":97},[3834],{"nctId":3812,"briefTitle":3813,"status":103,"phases":3835,"primaryCompletion":3815,"completion":3815,"start":3816,"enrollment":306,"conditions":3836,"interventions":3837},[86],[15],[3805,3819],{"trials":3839,"activeCount":97},[],{"trials":3841,"activeCount":97},[],{"trials":3843,"activeCount":97},[],{"trials":3845,"activeCount":97},[],{"intervention":3136,"totalTrials":264,"cells":3847},{"EARLY_PHASE1":3848,"PHASE1":3850,"PHASE2":3856,"PHASE3":3858,"PHASE4":3860,"NA":3862},{"trials":3849,"activeCount":97},[],{"trials":3851,"activeCount":97},[3852],{"nctId":3129,"briefTitle":3130,"status":252,"phases":3853,"primaryCompletion":3058,"completion":3058,"start":3132,"enrollment":229,"conditions":3854,"interventions":3855},[86],[3134],[3114,3136],{"trials":3857,"activeCount":97},[],{"trials":3859,"activeCount":97},[],{"trials":3861,"activeCount":97},[],{"trials":3863,"activeCount":97},[],{"intervention":3003,"totalTrials":264,"cells":3865},{"EARLY_PHASE1":3866,"PHASE1":3868,"PHASE2":3874,"PHASE3":3876,"PHASE4":3878,"NA":3880},{"trials":3867,"activeCount":97},[],{"trials":3869,"activeCount":97},[3870],{"nctId":2997,"briefTitle":2998,"status":103,"phases":3871,"primaryCompletion":3000,"start":1462,"enrollment":126,"conditions":3872,"interventions":3873},[86],[2980],[3003,3004,1034],{"trials":3875,"activeCount":97},[],{"trials":3877,"activeCount":97},[],{"trials":3879,"activeCount":97},[],{"trials":3881,"activeCount":97},[],{"intervention":3004,"totalTrials":264,"cells":3883},{"EARLY_PHASE1":3884,"PHASE1":3886,"PHASE2":3892,"PHASE3":3894,"PHASE4":3896,"NA":3898},{"trials":3885,"activeCount":97},[],{"trials":3887,"activeCount":97},[3888],{"nctId":2997,"briefTitle":2998,"status":103,"phases":3889,"primaryCompletion":3000,"start":1462,"enrollment":126,"conditions":3890,"interventions":3891},[86],[2980],[3003,3004,1034],{"trials":3893,"activeCount":97},[],{"trials":3895,"activeCount":97},[],{"trials":3897,"activeCount":97},[],{"trials":3899,"activeCount":97},[],{"intervention":579,"totalTrials":264,"cells":3901},{"EARLY_PHASE1":3902,"PHASE1":3904,"PHASE2":3910,"PHASE3":3912,"PHASE4":3914,"NA":3916},{"trials":3903,"activeCount":97},[],{"trials":3905,"activeCount":97},[3906],{"nctId":572,"briefTitle":573,"status":103,"phases":3907,"primaryCompletion":575,"completion":575,"start":576,"enrollment":503,"conditions":3908,"interventions":3909},[86],[15],[579,565],{"trials":3911,"activeCount":97},[],{"trials":3913,"activeCount":97},[],{"trials":3915,"activeCount":97},[],{"trials":3917,"activeCount":97},[],{"intervention":3919,"totalTrials":264,"cells":3920},"Lu AF76432",{"EARLY_PHASE1":3921,"PHASE1":3923,"PHASE2":3933,"PHASE3":3935,"PHASE4":3937,"NA":3939},{"trials":3922,"activeCount":97},[],{"trials":3924,"activeCount":97},[3925],{"nctId":3926,"briefTitle":3927,"status":103,"phases":3928,"primaryCompletion":3929,"completion":3929,"start":3930,"enrollment":393,"conditions":3931,"interventions":3932},"NCT03531229","Single Ascending Dose Study of Lu AF76432 in Healthy Young Men",[86],"2019-02-22","2018-04-17",[15],[3919],{"trials":3934,"activeCount":97},[],{"trials":3936,"activeCount":97},[],{"trials":3938,"activeCount":97},[],{"trials":3940,"activeCount":97},[],{"intervention":3942,"totalTrials":264,"cells":3943},"Flupentixol\u002Fmelitracen film-coated",{"EARLY_PHASE1":3944,"PHASE1":3946,"PHASE2":3956,"PHASE3":3958,"PHASE4":3960,"NA":3962},{"trials":3945,"activeCount":97},[],{"trials":3947,"activeCount":97},[3948],{"nctId":3949,"briefTitle":3950,"status":103,"phases":3951,"primaryCompletion":1245,"start":3000,"enrollment":416,"conditions":3952,"interventions":3954},"NCT02179931","Bioequivalence Study in Healthy Men and Women to Compare Two Pharmaceutical Formulations of Flupentixol\u002FMelitracen (Deanxit®)",[86],[3953],"Healthy Men and Women",[3942,3955],"Flupentixol\u002Fmelitracen coated",{"trials":3957,"activeCount":97},[],{"trials":3959,"activeCount":97},[],{"trials":3961,"activeCount":97},[],{"trials":3963,"activeCount":97},[],{"intervention":3955,"totalTrials":264,"cells":3965},{"EARLY_PHASE1":3966,"PHASE1":3968,"PHASE2":3974,"PHASE3":3976,"PHASE4":3978,"NA":3980},{"trials":3967,"activeCount":97},[],{"trials":3969,"activeCount":97},[3970],{"nctId":3949,"briefTitle":3950,"status":103,"phases":3971,"primaryCompletion":1245,"start":3000,"enrollment":416,"conditions":3972,"interventions":3973},[86],[3953],[3942,3955],{"trials":3975,"activeCount":97},[],{"trials":3977,"activeCount":97},[],{"trials":3979,"activeCount":97},[],{"trials":3981,"activeCount":97},[],{"intervention":3983,"totalTrials":264,"cells":3984},"Idalopirdine 60 mg formulation A",{"EARLY_PHASE1":3985,"PHASE1":3987,"PHASE2":3996,"PHASE3":3998,"PHASE4":4000,"NA":4002},{"trials":3986,"activeCount":97},[],{"trials":3988,"activeCount":97},[3989],{"nctId":3990,"briefTitle":3991,"status":103,"phases":3992,"primaryCompletion":3816,"completion":3816,"start":1840,"enrollment":416,"conditions":3993,"interventions":3994},"NCT02371707","Bioequivalence Study of Idalopirdine Tablets 60 mg",[86],[15],[3983,3995],"Idalopirdine 60 mg formulation B",{"trials":3997,"activeCount":97},[],{"trials":3999,"activeCount":97},[],{"trials":4001,"activeCount":97},[],{"trials":4003,"activeCount":97},[],{"intervention":3995,"totalTrials":264,"cells":4005},{"EARLY_PHASE1":4006,"PHASE1":4008,"PHASE2":4014,"PHASE3":4016,"PHASE4":4018,"NA":4020},{"trials":4007,"activeCount":97},[],{"trials":4009,"activeCount":97},[4010],{"nctId":3990,"briefTitle":3991,"status":103,"phases":4011,"primaryCompletion":3816,"completion":3816,"start":1840,"enrollment":416,"conditions":4012,"interventions":4013},[86],[15],[3983,3995],{"trials":4015,"activeCount":97},[],{"trials":4017,"activeCount":97},[],{"trials":4019,"activeCount":97},[],{"trials":4021,"activeCount":97},[],{"intervention":4023,"totalTrials":264,"cells":4024},"Lu AF90103",{"EARLY_PHASE1":4025,"PHASE1":4027,"PHASE2":4037,"PHASE3":4039,"PHASE4":4041,"NA":4043},{"trials":4026,"activeCount":97},[],{"trials":4028,"activeCount":97},[4029],{"nctId":4030,"briefTitle":4031,"status":252,"phases":4032,"primaryCompletion":4033,"completion":4033,"start":4034,"enrollment":25,"conditions":4035,"interventions":4036},"NCT04940949","A Study to Evaluate Lu AF90103 in Healthy Men",[86],"2021-11-23","2021-05-26",[15],[4023],{"trials":4038,"activeCount":97},[],{"trials":4040,"activeCount":97},[],{"trials":4042,"activeCount":97},[],{"trials":4044,"activeCount":97},[],{"intervention":3161,"totalTrials":264,"cells":4046},{"EARLY_PHASE1":4047,"PHASE1":4049,"PHASE2":4055,"PHASE3":4057,"PHASE4":4059,"NA":4061},{"trials":4048,"activeCount":97},[],{"trials":4050,"activeCount":97},[4051],{"nctId":3153,"briefTitle":3154,"status":103,"phases":4052,"primaryCompletion":3156,"completion":3156,"start":3157,"enrollment":3158,"conditions":4053,"interventions":4054},[86],[15],[3146,3161,3162],{"trials":4056,"activeCount":97},[],{"trials":4058,"activeCount":97},[],{"trials":4060,"activeCount":97},[],{"trials":4062,"activeCount":97},[],{"intervention":3162,"totalTrials":264,"cells":4064},{"EARLY_PHASE1":4065,"PHASE1":4067,"PHASE2":4073,"PHASE3":4075,"PHASE4":4077,"NA":4079},{"trials":4066,"activeCount":97},[],{"trials":4068,"activeCount":97},[4069],{"nctId":3153,"briefTitle":3154,"status":103,"phases":4070,"primaryCompletion":3156,"completion":3156,"start":3157,"enrollment":3158,"conditions":4071,"interventions":4072},[86],[15],[3146,3161,3162],{"trials":4074,"activeCount":97},[],{"trials":4076,"activeCount":97},[],{"trials":4078,"activeCount":97},[],{"trials":4080,"activeCount":97},[],{"intervention":4082,"totalTrials":264,"cells":4083},"Nalmefene 18 mg, then placebo",{"EARLY_PHASE1":4084,"PHASE1":4086,"PHASE2":4095,"PHASE3":4097,"PHASE4":4099,"NA":4101},{"trials":4085,"activeCount":97},[],{"trials":4087,"activeCount":97},[4088],{"nctId":4089,"briefTitle":4090,"status":103,"phases":4091,"primaryCompletion":1601,"start":4092,"enrollment":325,"conditions":4093,"interventions":4094},"NCT01969617","Effects of Nalmefene After Single Dose on the Blood Oxygen Level Dependent (BOLD) fMRI Signal in the Ventral Striatum to Reward Responding in the Monetary Incentive Delay Task (MIDT), in Non-treatment Seeking Subjects With Alcohol Dependence Following Alcohol Challenge",[86],"2013-11",[790],[4082],{"trials":4096,"activeCount":97},[],{"trials":4098,"activeCount":97},[],{"trials":4100,"activeCount":97},[],{"trials":4102,"activeCount":97},[],{"intervention":4104,"totalTrials":264,"cells":4105},"ALD1910",{"EARLY_PHASE1":4106,"PHASE1":4108,"PHASE2":4119,"PHASE3":4121,"PHASE4":4123,"NA":4125},{"trials":4107,"activeCount":97},[],{"trials":4109,"activeCount":97},[4110],{"nctId":4111,"briefTitle":4112,"status":103,"phases":4113,"primaryCompletion":4114,"completion":4114,"start":4115,"enrollment":696,"conditions":4116,"interventions":4117},"NCT04197349","Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman",[86],"2020-08-19","2019-09-24",[24],[4104,4118,4104],"Sumatriptan",{"trials":4120,"activeCount":97},[],{"trials":4122,"activeCount":97},[],{"trials":4124,"activeCount":97},[],{"trials":4126,"activeCount":97},[],{"intervention":4118,"totalTrials":264,"cells":4128},{"EARLY_PHASE1":4129,"PHASE1":4131,"PHASE2":4137,"PHASE3":4139,"PHASE4":4141,"NA":4143},{"trials":4130,"activeCount":97},[],{"trials":4132,"activeCount":97},[4133],{"nctId":4111,"briefTitle":4112,"status":103,"phases":4134,"primaryCompletion":4114,"completion":4114,"start":4115,"enrollment":696,"conditions":4135,"interventions":4136},[86],[24],[4104,4118,4104],{"trials":4138,"activeCount":97},[],{"trials":4140,"activeCount":97},[],{"trials":4142,"activeCount":97},[],{"trials":4144,"activeCount":97},[],{"intervention":4146,"totalTrials":264,"cells":4147},"Eptinezumab Mammalian Cell Line",{"EARLY_PHASE1":4148,"PHASE1":4150,"PHASE2":4161,"PHASE3":4163,"PHASE4":4165,"NA":4167},{"trials":4149,"activeCount":97},[],{"trials":4151,"activeCount":97},[4152],{"nctId":4153,"briefTitle":4154,"status":103,"phases":4155,"primaryCompletion":4156,"completion":4156,"start":2900,"enrollment":4157,"conditions":4158,"interventions":4159},"NCT05074459","A Study in Healthy Adults Investigating Eptinezumab Produced by 2 Different Manufacturing Cell Lines",[86],"2022-07-18",84,[32],[4146,4160],"Eptinezumab Yeast Cell Line",{"trials":4162,"activeCount":97},[],{"trials":4164,"activeCount":97},[],{"trials":4166,"activeCount":97},[],{"trials":4168,"activeCount":97},[],{"intervention":4160,"totalTrials":264,"cells":4170},{"EARLY_PHASE1":4171,"PHASE1":4173,"PHASE2":4179,"PHASE3":4181,"PHASE4":4183,"NA":4185},{"trials":4172,"activeCount":97},[],{"trials":4174,"activeCount":97},[4175],{"nctId":4153,"briefTitle":4154,"status":103,"phases":4176,"primaryCompletion":4156,"completion":4156,"start":2900,"enrollment":4157,"conditions":4177,"interventions":4178},[86],[32],[4146,4160],{"trials":4180,"activeCount":97},[],{"trials":4182,"activeCount":97},[],{"trials":4184,"activeCount":97},[],{"trials":4186,"activeCount":97},[],{"intervention":4188,"totalTrials":264,"cells":4189},"Lu AF35700 5 mg clinical formulation",{"EARLY_PHASE1":4190,"PHASE1":4192,"PHASE2":4207,"PHASE3":4209,"PHASE4":4211,"NA":4213},{"trials":4191,"activeCount":97},[],{"trials":4193,"activeCount":97},[4194],{"nctId":4195,"briefTitle":4196,"status":103,"phases":4197,"primaryCompletion":4198,"completion":4198,"start":1039,"enrollment":4199,"conditions":4200,"interventions":4201},"NCT03394482","Bioequivalence Study of Lu AF35700",[86],"2018-10-05",87,[15],[4188,4202,4203,4204,4205,4206],"Lu AF35700 5 mg commercial formulation","Lu AF35700 10 mg clinical formulation","Lu AF35700 10 mg commercial formulation","Lu AF35700 20 mg clinical formulation","Lu AF35700 20 mg commercial formulation",{"trials":4208,"activeCount":97},[],{"trials":4210,"activeCount":97},[],{"trials":4212,"activeCount":97},[],{"trials":4214,"activeCount":97},[],{"intervention":4202,"totalTrials":264,"cells":4216},{"EARLY_PHASE1":4217,"PHASE1":4219,"PHASE2":4225,"PHASE3":4227,"PHASE4":4229,"NA":4231},{"trials":4218,"activeCount":97},[],{"trials":4220,"activeCount":97},[4221],{"nctId":4195,"briefTitle":4196,"status":103,"phases":4222,"primaryCompletion":4198,"completion":4198,"start":1039,"enrollment":4199,"conditions":4223,"interventions":4224},[86],[15],[4188,4202,4203,4204,4205,4206],{"trials":4226,"activeCount":97},[],{"trials":4228,"activeCount":97},[],{"trials":4230,"activeCount":97},[],{"trials":4232,"activeCount":97},[],{"intervention":4203,"totalTrials":264,"cells":4234},{"EARLY_PHASE1":4235,"PHASE1":4237,"PHASE2":4243,"PHASE3":4245,"PHASE4":4247,"NA":4249},{"trials":4236,"activeCount":97},[],{"trials":4238,"activeCount":97},[4239],{"nctId":4195,"briefTitle":4196,"status":103,"phases":4240,"primaryCompletion":4198,"completion":4198,"start":1039,"enrollment":4199,"conditions":4241,"interventions":4242},[86],[15],[4188,4202,4203,4204,4205,4206],{"trials":4244,"activeCount":97},[],{"trials":4246,"activeCount":97},[],{"trials":4248,"activeCount":97},[],{"trials":4250,"activeCount":97},[],{"intervention":4204,"totalTrials":264,"cells":4252},{"EARLY_PHASE1":4253,"PHASE1":4255,"PHASE2":4261,"PHASE3":4263,"PHASE4":4265,"NA":4267},{"trials":4254,"activeCount":97},[],{"trials":4256,"activeCount":97},[4257],{"nctId":4195,"briefTitle":4196,"status":103,"phases":4258,"primaryCompletion":4198,"completion":4198,"start":1039,"enrollment":4199,"conditions":4259,"interventions":4260},[86],[15],[4188,4202,4203,4204,4205,4206],{"trials":4262,"activeCount":97},[],{"trials":4264,"activeCount":97},[],{"trials":4266,"activeCount":97},[],{"trials":4268,"activeCount":97},[],{"intervention":4205,"totalTrials":264,"cells":4270},{"EARLY_PHASE1":4271,"PHASE1":4273,"PHASE2":4279,"PHASE3":4281,"PHASE4":4283,"NA":4285},{"trials":4272,"activeCount":97},[],{"trials":4274,"activeCount":97},[4275],{"nctId":4195,"briefTitle":4196,"status":103,"phases":4276,"primaryCompletion":4198,"completion":4198,"start":1039,"enrollment":4199,"conditions":4277,"interventions":4278},[86],[15],[4188,4202,4203,4204,4205,4206],{"trials":4280,"activeCount":97},[],{"trials":4282,"activeCount":97},[],{"trials":4284,"activeCount":97},[],{"trials":4286,"activeCount":97},[],{"intervention":4206,"totalTrials":264,"cells":4288},{"EARLY_PHASE1":4289,"PHASE1":4291,"PHASE2":4297,"PHASE3":4299,"PHASE4":4301,"NA":4303},{"trials":4290,"activeCount":97},[],{"trials":4292,"activeCount":97},[4293],{"nctId":4195,"briefTitle":4196,"status":103,"phases":4294,"primaryCompletion":4198,"completion":4198,"start":1039,"enrollment":4199,"conditions":4295,"interventions":4296},[86],[15],[4188,4202,4203,4204,4205,4206],{"trials":4298,"activeCount":97},[],{"trials":4300,"activeCount":97},[],{"trials":4302,"activeCount":97},[],{"trials":4304,"activeCount":97},[],{"intervention":1023,"totalTrials":264,"cells":4306},{"EARLY_PHASE1":4307,"PHASE1":4309,"PHASE2":4315,"PHASE3":4317,"PHASE4":4319,"NA":4321},{"trials":4308,"activeCount":97},[],{"trials":4310,"activeCount":97},[4311],{"nctId":1015,"briefTitle":1016,"status":103,"phases":4312,"primaryCompletion":1018,"completion":1019,"start":1020,"enrollment":28,"conditions":4313,"interventions":4314},[86],[15],[1007,1023],{"trials":4316,"activeCount":97},[],{"trials":4318,"activeCount":97},[],{"trials":4320,"activeCount":97},[],{"trials":4322,"activeCount":97},[],{"intervention":1044,"totalTrials":264,"cells":4324},{"EARLY_PHASE1":4325,"PHASE1":4327,"PHASE2":4333,"PHASE3":4335,"PHASE4":4337,"NA":4339},{"trials":4326,"activeCount":97},[],{"trials":4328,"activeCount":97},[4329],{"nctId":1036,"briefTitle":1037,"status":103,"phases":4330,"primaryCompletion":1039,"completion":1039,"start":1040,"enrollment":494,"conditions":4331,"interventions":4332},[86],[1042],[1007,1044,1045],{"trials":4334,"activeCount":97},[],{"trials":4336,"activeCount":97},[],{"trials":4338,"activeCount":97},[],{"trials":4340,"activeCount":97},[],{"intervention":1045,"totalTrials":264,"cells":4342},{"EARLY_PHASE1":4343,"PHASE1":4345,"PHASE2":4351,"PHASE3":4353,"PHASE4":4355,"NA":4357},{"trials":4344,"activeCount":97},[],{"trials":4346,"activeCount":97},[4347],{"nctId":1036,"briefTitle":1037,"status":103,"phases":4348,"primaryCompletion":1039,"completion":1039,"start":1040,"enrollment":494,"conditions":4349,"interventions":4350},[86],[1042],[1007,1044,1045],{"trials":4352,"activeCount":97},[],{"trials":4354,"activeCount":97},[],{"trials":4356,"activeCount":97},[],{"trials":4358,"activeCount":97},[],{"intervention":429,"totalTrials":264,"cells":4360},{"EARLY_PHASE1":4361,"PHASE1":4363,"PHASE2":4369,"PHASE3":4371,"PHASE4":4373,"NA":4375},{"trials":4362,"activeCount":97},[],{"trials":4364,"activeCount":97},[4365],{"nctId":421,"briefTitle":422,"status":103,"phases":4366,"primaryCompletion":424,"completion":424,"start":425,"enrollment":426,"conditions":4367,"interventions":4368},[86],[24],[429,46],{"trials":4370,"activeCount":97},[],{"trials":4372,"activeCount":97},[],{"trials":4374,"activeCount":97},[],{"trials":4376,"activeCount":97},[],{"intervention":341,"totalTrials":264,"cells":4378},{"EARLY_PHASE1":4379,"PHASE1":4381,"PHASE2":4387,"PHASE3":4389,"PHASE4":4391,"NA":4393},{"trials":4380,"activeCount":97},[],{"trials":4382,"activeCount":97},[4383],{"nctId":332,"briefTitle":333,"status":103,"phases":4384,"primaryCompletion":335,"completion":336,"start":337,"enrollment":338,"conditions":4385,"interventions":4386},[86],[15],[341,79],{"trials":4388,"activeCount":97},[],{"trials":4390,"activeCount":97},[],{"trials":4392,"activeCount":97},[],{"trials":4394,"activeCount":97},[],{"intervention":4396,"totalTrials":264,"cells":4397},"[14C]-Lu AG06466",{"EARLY_PHASE1":4398,"PHASE1":4400,"PHASE2":4410,"PHASE3":4412,"PHASE4":4414,"NA":4416},{"trials":4399,"activeCount":97},[],{"trials":4401,"activeCount":97},[4402],{"nctId":4403,"briefTitle":4404,"status":103,"phases":4405,"primaryCompletion":4406,"completion":4406,"start":4407,"enrollment":306,"conditions":4408,"interventions":4409},"NCT05201092","A Study Investigating Lu AG06466 in Healthy Men",[86],"2022-02-19","2022-01-05",[2980],[4396],{"trials":4411,"activeCount":97},[],{"trials":4413,"activeCount":97},[],{"trials":4415,"activeCount":97},[],{"trials":4417,"activeCount":97},[],{"intervention":3094,"totalTrials":264,"cells":4419},{"EARLY_PHASE1":4420,"PHASE1":4422,"PHASE2":4428,"PHASE3":4430,"PHASE4":4432,"NA":4434},{"trials":4421,"activeCount":97},[],{"trials":4423,"activeCount":97},[4424],{"nctId":3086,"briefTitle":3087,"status":103,"phases":4425,"primaryCompletion":3089,"completion":3090,"start":3091,"enrollment":1256,"conditions":4426,"interventions":4427},[86],[32],[3070,3094,3095],{"trials":4429,"activeCount":97},[],{"trials":4431,"activeCount":97},[],{"trials":4433,"activeCount":97},[],{"trials":4435,"activeCount":97},[],{"intervention":3095,"totalTrials":264,"cells":4437},{"EARLY_PHASE1":4438,"PHASE1":4440,"PHASE2":4446,"PHASE3":4448,"PHASE4":4450,"NA":4452},{"trials":4439,"activeCount":97},[],{"trials":4441,"activeCount":97},[4442],{"nctId":3086,"briefTitle":3087,"status":103,"phases":4443,"primaryCompletion":3089,"completion":3090,"start":3091,"enrollment":1256,"conditions":4444,"interventions":4445},[86],[32],[3070,3094,3095],{"trials":4447,"activeCount":97},[],{"trials":4449,"activeCount":97},[],{"trials":4451,"activeCount":97},[],{"trials":4453,"activeCount":97},[],{"intervention":2371,"totalTrials":264,"cells":4455},{"EARLY_PHASE1":4456,"PHASE1":4458,"PHASE2":4464,"PHASE3":4466,"PHASE4":4468,"NA":4470},{"trials":4457,"activeCount":97},[],{"trials":4459,"activeCount":97},[4460],{"nctId":2363,"briefTitle":2364,"status":103,"phases":4461,"primaryCompletion":2366,"completion":2366,"start":2367,"enrollment":2368,"conditions":4462,"interventions":4463},[86],[15],[2337,2371,2372],{"trials":4465,"activeCount":97},[],{"trials":4467,"activeCount":97},[],{"trials":4469,"activeCount":97},[],{"trials":4471,"activeCount":97},[],{"intervention":2372,"totalTrials":264,"cells":4473},{"EARLY_PHASE1":4474,"PHASE1":4476,"PHASE2":4482,"PHASE3":4484,"PHASE4":4486,"NA":4488},{"trials":4475,"activeCount":97},[],{"trials":4477,"activeCount":97},[4478],{"nctId":2363,"briefTitle":2364,"status":103,"phases":4479,"primaryCompletion":2366,"completion":2366,"start":2367,"enrollment":2368,"conditions":4480,"interventions":4481},[86],[15],[2337,2371,2372],{"trials":4483,"activeCount":97},[],{"trials":4485,"activeCount":97},[],{"trials":4487,"activeCount":97},[],{"trials":4489,"activeCount":97},[],{"intervention":4491,"totalTrials":264,"cells":4492},"[11C]-Lu AF90103",{"EARLY_PHASE1":4493,"PHASE1":4495,"PHASE2":4506,"PHASE3":4508,"PHASE4":4510,"NA":4512},{"trials":4494,"activeCount":97},[],{"trials":4496,"activeCount":97},[4497],{"nctId":4498,"briefTitle":4499,"status":103,"phases":4500,"primaryCompletion":4501,"completion":4501,"start":4502,"enrollment":11,"conditions":4503,"interventions":4505},"NCT05306366","A Brain Imaging PET Study of [11C]-Lu AF90103 in Healthy Adult Male Participants",[86],"2022-06-07","2022-03-23",[4504],"Healthy Young Men",[4491],{"trials":4507,"activeCount":97},[],{"trials":4509,"activeCount":97},[],{"trials":4511,"activeCount":97},[],{"trials":4513,"activeCount":97},[],{"intervention":4515,"totalTrials":264,"cells":4516},"Idalopirdine commercial",{"EARLY_PHASE1":4517,"PHASE1":4519,"PHASE2":4529,"PHASE3":4531,"PHASE4":4533,"NA":4535},{"trials":4518,"activeCount":97},[],{"trials":4520,"activeCount":97},[4521],{"nctId":4522,"briefTitle":4523,"status":1234,"phases":4524,"primaryCompletion":1061,"completion":1061,"start":1061,"enrollment":97,"conditions":4525,"interventions":4527},"NCT02894515","Bioequivalence Study of Idalopirdine in Healthy Subjects",[86],[4526],"Bioequivalence",[4515,4528],"Idalopirdine clinical",{"trials":4530,"activeCount":97},[],{"trials":4532,"activeCount":97},[],{"trials":4534,"activeCount":97},[],{"trials":4536,"activeCount":97},[],{"intervention":4528,"totalTrials":264,"cells":4538},{"EARLY_PHASE1":4539,"PHASE1":4541,"PHASE2":4547,"PHASE3":4549,"PHASE4":4551,"NA":4553},{"trials":4540,"activeCount":97},[],{"trials":4542,"activeCount":97},[4543],{"nctId":4522,"briefTitle":4523,"status":1234,"phases":4544,"primaryCompletion":1061,"completion":1061,"start":1061,"enrollment":97,"conditions":4545,"interventions":4546},[86],[4526],[4515,4528],{"trials":4548,"activeCount":97},[],{"trials":4550,"activeCount":97},[],{"trials":4552,"activeCount":97},[],{"trials":4554,"activeCount":97},[],{"intervention":4556,"totalTrials":264,"cells":4557},"[11C]-Lu AF88370",{"EARLY_PHASE1":4558,"PHASE1":4560,"PHASE2":4571,"PHASE3":4573,"PHASE4":4575,"NA":4577},{"trials":4559,"activeCount":97},[],{"trials":4561,"activeCount":97},[4562],{"nctId":4563,"briefTitle":4564,"status":103,"phases":4565,"primaryCompletion":4566,"completion":4567,"start":4568,"enrollment":306,"conditions":4569,"interventions":4570},"NCT05320302","A Brain Imaging PET Study of [11C]-Lu AF88370 in Healthy Adult Male Participants",[86],"2022-06-15","2022-06-20","2022-03-31",[32],[4556],{"trials":4572,"activeCount":97},[],{"trials":4574,"activeCount":97},[],{"trials":4576,"activeCount":97},[],{"trials":4578,"activeCount":97},[],{"intervention":4580,"totalTrials":264,"cells":4581},"Part A: Lu AF35700",{"EARLY_PHASE1":4582,"PHASE1":4584,"PHASE2":4593,"PHASE3":4595,"PHASE4":4597,"NA":4599},{"trials":4583,"activeCount":97},[],{"trials":4585,"activeCount":97},[4586],{"nctId":4587,"briefTitle":4588,"status":103,"phases":4589,"primaryCompletion":3000,"start":1453,"enrollment":1713,"conditions":4590,"interventions":4591},"NCT02093169","D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound",[86],[1580],[4580,4592],"Part B: Lu AF35700",{"trials":4594,"activeCount":97},[],{"trials":4596,"activeCount":97},[],{"trials":4598,"activeCount":97},[],{"trials":4600,"activeCount":97},[],{"intervention":4592,"totalTrials":264,"cells":4602},{"EARLY_PHASE1":4603,"PHASE1":4605,"PHASE2":4611,"PHASE3":4613,"PHASE4":4615,"NA":4617},{"trials":4604,"activeCount":97},[],{"trials":4606,"activeCount":97},[4607],{"nctId":4587,"briefTitle":4588,"status":103,"phases":4608,"primaryCompletion":3000,"start":1453,"enrollment":1713,"conditions":4609,"interventions":4610},[86],[1580],[4580,4592],{"trials":4612,"activeCount":97},[],{"trials":4614,"activeCount":97},[],{"trials":4616,"activeCount":97},[],{"trials":4618,"activeCount":97},[],{"intervention":4620,"totalTrials":264,"cells":4621},"ldalopirdine 120 mg",{"EARLY_PHASE1":4622,"PHASE1":4624,"PHASE2":4636,"PHASE3":4638,"PHASE4":4640,"NA":4642},{"trials":4623,"activeCount":97},[],{"trials":4625,"activeCount":97},[4626],{"nctId":4627,"briefTitle":4628,"status":103,"phases":4629,"primaryCompletion":1906,"start":4630,"enrollment":4631,"conditions":4632,"interventions":4633},"NCT02436486","Study Investigating the Effect of Idalopirdine on Cardiac Repolarisation in Healthy Men",[86],"2015-05",76,[2980],[4620,4634,4635],"Idalopirdine 360 mg","Moxifloxacin 400 mg",{"trials":4637,"activeCount":97},[],{"trials":4639,"activeCount":97},[],{"trials":4641,"activeCount":97},[],{"trials":4643,"activeCount":97},[],{"intervention":4634,"totalTrials":264,"cells":4645},{"EARLY_PHASE1":4646,"PHASE1":4648,"PHASE2":4654,"PHASE3":4656,"PHASE4":4658,"NA":4660},{"trials":4647,"activeCount":97},[],{"trials":4649,"activeCount":97},[4650],{"nctId":4627,"briefTitle":4628,"status":103,"phases":4651,"primaryCompletion":1906,"start":4630,"enrollment":4631,"conditions":4652,"interventions":4653},[86],[2980],[4620,4634,4635],{"trials":4655,"activeCount":97},[],{"trials":4657,"activeCount":97},[],{"trials":4659,"activeCount":97},[],{"trials":4661,"activeCount":97},[],{"intervention":4635,"totalTrials":264,"cells":4663},{"EARLY_PHASE1":4664,"PHASE1":4666,"PHASE2":4672,"PHASE3":4674,"PHASE4":4676,"NA":4678},{"trials":4665,"activeCount":97},[],{"trials":4667,"activeCount":97},[4668],{"nctId":4627,"briefTitle":4628,"status":103,"phases":4669,"primaryCompletion":1906,"start":4630,"enrollment":4631,"conditions":4670,"interventions":4671},[86],[2980],[4620,4634,4635],{"trials":4673,"activeCount":97},[],{"trials":4675,"activeCount":97},[],{"trials":4677,"activeCount":97},[],{"trials":4679,"activeCount":97},[],{"intervention":4681,"totalTrials":264,"cells":4682},"0.5 mg Flupentixol film-coated",{"EARLY_PHASE1":4683,"PHASE1":4685,"PHASE2":4699,"PHASE3":4701,"PHASE4":4703,"NA":4705},{"trials":4684,"activeCount":97},[],{"trials":4686,"activeCount":97},[4687],{"nctId":4688,"briefTitle":4689,"status":103,"phases":4690,"primaryCompletion":1236,"start":3545,"enrollment":4157,"conditions":4691,"interventions":4693},"NCT02660840","Comparative Study of the Pharmacokinetics and Bioequivalence of Two Flupentixol Formulations",[86],[4692],"Bioequivalence Study in Healthy Subjects",[4681,4694,4695,4696,4697,4698],"1 mg Flupentixol film-coated","5 mg Flupentixol film-coated","0.5 mg Flupentixol coated","1 mg Flupentixol coated","5 mg Flupentixol coated",{"trials":4700,"activeCount":97},[],{"trials":4702,"activeCount":97},[],{"trials":4704,"activeCount":97},[],{"trials":4706,"activeCount":97},[],{"intervention":4694,"totalTrials":264,"cells":4708},{"EARLY_PHASE1":4709,"PHASE1":4711,"PHASE2":4717,"PHASE3":4719,"PHASE4":4721,"NA":4723},{"trials":4710,"activeCount":97},[],{"trials":4712,"activeCount":97},[4713],{"nctId":4688,"briefTitle":4689,"status":103,"phases":4714,"primaryCompletion":1236,"start":3545,"enrollment":4157,"conditions":4715,"interventions":4716},[86],[4692],[4681,4694,4695,4696,4697,4698],{"trials":4718,"activeCount":97},[],{"trials":4720,"activeCount":97},[],{"trials":4722,"activeCount":97},[],{"trials":4724,"activeCount":97},[],{"intervention":4695,"totalTrials":264,"cells":4726},{"EARLY_PHASE1":4727,"PHASE1":4729,"PHASE2":4735,"PHASE3":4737,"PHASE4":4739,"NA":4741},{"trials":4728,"activeCount":97},[],{"trials":4730,"activeCount":97},[4731],{"nctId":4688,"briefTitle":4689,"status":103,"phases":4732,"primaryCompletion":1236,"start":3545,"enrollment":4157,"conditions":4733,"interventions":4734},[86],[4692],[4681,4694,4695,4696,4697,4698],{"trials":4736,"activeCount":97},[],{"trials":4738,"activeCount":97},[],{"trials":4740,"activeCount":97},[],{"trials":4742,"activeCount":97},[],{"intervention":4696,"totalTrials":264,"cells":4744},{"EARLY_PHASE1":4745,"PHASE1":4747,"PHASE2":4753,"PHASE3":4755,"PHASE4":4757,"NA":4759},{"trials":4746,"activeCount":97},[],{"trials":4748,"activeCount":97},[4749],{"nctId":4688,"briefTitle":4689,"status":103,"phases":4750,"primaryCompletion":1236,"start":3545,"enrollment":4157,"conditions":4751,"interventions":4752},[86],[4692],[4681,4694,4695,4696,4697,4698],{"trials":4754,"activeCount":97},[],{"trials":4756,"activeCount":97},[],{"trials":4758,"activeCount":97},[],{"trials":4760,"activeCount":97},[],{"intervention":4697,"totalTrials":264,"cells":4762},{"EARLY_PHASE1":4763,"PHASE1":4765,"PHASE2":4771,"PHASE3":4773,"PHASE4":4775,"NA":4777},{"trials":4764,"activeCount":97},[],{"trials":4766,"activeCount":97},[4767],{"nctId":4688,"briefTitle":4689,"status":103,"phases":4768,"primaryCompletion":1236,"start":3545,"enrollment":4157,"conditions":4769,"interventions":4770},[86],[4692],[4681,4694,4695,4696,4697,4698],{"trials":4772,"activeCount":97},[],{"trials":4774,"activeCount":97},[],{"trials":4776,"activeCount":97},[],{"trials":4778,"activeCount":97},[],{"intervention":4698,"totalTrials":264,"cells":4780},{"EARLY_PHASE1":4781,"PHASE1":4783,"PHASE2":4789,"PHASE3":4791,"PHASE4":4793,"NA":4795},{"trials":4782,"activeCount":97},[],{"trials":4784,"activeCount":97},[4785],{"nctId":4688,"briefTitle":4689,"status":103,"phases":4786,"primaryCompletion":1236,"start":3545,"enrollment":4157,"conditions":4787,"interventions":4788},[86],[4692],[4681,4694,4695,4696,4697,4698],{"trials":4790,"activeCount":97},[],{"trials":4792,"activeCount":97},[],{"trials":4794,"activeCount":97},[],{"trials":4796,"activeCount":97},[],{"intervention":4798,"totalTrials":264,"cells":4799},"Cohort A1: Lu AE58054 or placebo",{"EARLY_PHASE1":4800,"PHASE1":4802,"PHASE2":4812,"PHASE3":4814,"PHASE4":4816,"NA":4818},{"trials":4801,"activeCount":97},[],{"trials":4803,"activeCount":97},[4804],{"nctId":4805,"briefTitle":4806,"status":103,"phases":4807,"primaryCompletion":1246,"start":1291,"enrollment":393,"conditions":4808,"interventions":4809},"NCT01975779","Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AE58054 in Healthy Japanese and Caucasian Subjects",[86],[15],[4798,4810,4811],"Cohort A2: Lu AE58054 or placebo","Cohort B1: Lu AE58054",{"trials":4813,"activeCount":97},[],{"trials":4815,"activeCount":97},[],{"trials":4817,"activeCount":97},[],{"trials":4819,"activeCount":97},[],{"intervention":4810,"totalTrials":264,"cells":4821},{"EARLY_PHASE1":4822,"PHASE1":4824,"PHASE2":4830,"PHASE3":4832,"PHASE4":4834,"NA":4836},{"trials":4823,"activeCount":97},[],{"trials":4825,"activeCount":97},[4826],{"nctId":4805,"briefTitle":4806,"status":103,"phases":4827,"primaryCompletion":1246,"start":1291,"enrollment":393,"conditions":4828,"interventions":4829},[86],[15],[4798,4810,4811],{"trials":4831,"activeCount":97},[],{"trials":4833,"activeCount":97},[],{"trials":4835,"activeCount":97},[],{"trials":4837,"activeCount":97},[],{"intervention":4811,"totalTrials":264,"cells":4839},{"EARLY_PHASE1":4840,"PHASE1":4842,"PHASE2":4848,"PHASE3":4850,"PHASE4":4852,"NA":4854},{"trials":4841,"activeCount":97},[],{"trials":4843,"activeCount":97},[4844],{"nctId":4805,"briefTitle":4806,"status":103,"phases":4845,"primaryCompletion":1246,"start":1291,"enrollment":393,"conditions":4846,"interventions":4847},[86],[15],[4798,4810,4811],{"trials":4849,"activeCount":97},[],{"trials":4851,"activeCount":97},[],{"trials":4853,"activeCount":97},[],{"trials":4855,"activeCount":97},[],{"intervention":3171,"totalTrials":264,"cells":4857},{"EARLY_PHASE1":4858,"PHASE1":4860,"PHASE2":4866,"PHASE3":4868,"PHASE4":4870,"NA":4872},{"trials":4859,"activeCount":97},[],{"trials":4861,"activeCount":97},[4862],{"nctId":3164,"briefTitle":3165,"status":103,"phases":4863,"primaryCompletion":3167,"completion":3167,"start":3168,"enrollment":11,"conditions":4864,"interventions":4865},[86],[15],[3146,3171],{"trials":4867,"activeCount":97},[],{"trials":4869,"activeCount":97},[],{"trials":4871,"activeCount":97},[],{"trials":4873,"activeCount":97},[],{"intervention":1583,"totalTrials":264,"cells":4875},{"EARLY_PHASE1":4876,"PHASE1":4878,"PHASE2":4884,"PHASE3":4886,"PHASE4":4888,"NA":4890},{"trials":4877,"activeCount":97},[],{"trials":4879,"activeCount":97},[4880],{"nctId":1575,"briefTitle":1576,"status":103,"phases":4881,"primaryCompletion":1578,"start":1453,"enrollment":257,"conditions":4882,"interventions":4883},[86],[1580],[1568,1582,1583],{"trials":4885,"activeCount":97},[],{"trials":4887,"activeCount":97},[],{"trials":4889,"activeCount":97},[],{"trials":4891,"activeCount":97},[],{"intervention":2973,"totalTrials":264,"cells":4893},{"EARLY_PHASE1":4894,"PHASE1":4896,"PHASE2":4902,"PHASE3":4904,"PHASE4":4906,"NA":4908},{"trials":4895,"activeCount":97},[],{"trials":4897,"activeCount":97},[4898],{"nctId":2966,"briefTitle":2967,"status":103,"phases":4899,"primaryCompletion":2969,"completion":2969,"start":2970,"enrollment":93,"conditions":4900,"interventions":4901},[86],[15],[2889,2889,2973],{"trials":4903,"activeCount":97},[],{"trials":4905,"activeCount":97},[],{"trials":4907,"activeCount":97},[],{"trials":4909,"activeCount":97},[],{"intervention":4911,"totalTrials":264,"cells":4912},"Foliglurax 10 mg",{"EARLY_PHASE1":4913,"PHASE1":4915,"PHASE2":4926,"PHASE3":4928,"PHASE4":4930,"NA":4932},{"trials":4914,"activeCount":97},[],{"trials":4916,"activeCount":97},[4917],{"nctId":4918,"briefTitle":4919,"status":252,"phases":4920,"primaryCompletion":4921,"completion":4921,"start":4922,"enrollment":306,"conditions":4923,"interventions":4924},"NCT04322227","Study Investigating Effects of Foliglurax in Patients With Parkinson's Disease (PD) and Healthy Subjects",[86],"2020-05-30","2020-01-23",[35,15],[4911,4925],"Foliglurax 30 mg",{"trials":4927,"activeCount":97},[],{"trials":4929,"activeCount":97},[],{"trials":4931,"activeCount":97},[],{"trials":4933,"activeCount":97},[],{"intervention":4925,"totalTrials":264,"cells":4935},{"EARLY_PHASE1":4936,"PHASE1":4938,"PHASE2":4944,"PHASE3":4946,"PHASE4":4948,"NA":4950},{"trials":4937,"activeCount":97},[],{"trials":4939,"activeCount":97},[4940],{"nctId":4918,"briefTitle":4919,"status":252,"phases":4941,"primaryCompletion":4921,"completion":4921,"start":4922,"enrollment":306,"conditions":4942,"interventions":4943},[86],[35,15],[4911,4925],{"trials":4945,"activeCount":97},[],{"trials":4947,"activeCount":97},[],{"trials":4949,"activeCount":97},[],{"trials":4951,"activeCount":97},[],{"intervention":4953,"totalTrials":264,"cells":4954},"Vortioxetine 10 mg single dose",{"EARLY_PHASE1":4955,"PHASE1":4957,"PHASE2":4969,"PHASE3":4971,"PHASE4":4973,"NA":4975},{"trials":4956,"activeCount":97},[],{"trials":4958,"activeCount":97},[4959],{"nctId":4960,"briefTitle":4961,"status":103,"phases":4962,"primaryCompletion":4630,"completion":4630,"start":1840,"enrollment":503,"conditions":4963,"interventions":4965},"NCT02386488","Pharmacokinetic Properties of Vortioxetine in Healthy Young Chinese Men and Women",[86],[4964],"Pharmacokinetics",[4953,4966,4967,4968],"Vortioxetine 20 mg single dose","Vortioxetine 10 mg multiple dose","Vortioxetine 20 mg multiple dose",{"trials":4970,"activeCount":97},[],{"trials":4972,"activeCount":97},[],{"trials":4974,"activeCount":97},[],{"trials":4976,"activeCount":97},[],{"intervention":4966,"totalTrials":264,"cells":4978},{"EARLY_PHASE1":4979,"PHASE1":4981,"PHASE2":4987,"PHASE3":4989,"PHASE4":4991,"NA":4993},{"trials":4980,"activeCount":97},[],{"trials":4982,"activeCount":97},[4983],{"nctId":4960,"briefTitle":4961,"status":103,"phases":4984,"primaryCompletion":4630,"completion":4630,"start":1840,"enrollment":503,"conditions":4985,"interventions":4986},[86],[4964],[4953,4966,4967,4968],{"trials":4988,"activeCount":97},[],{"trials":4990,"activeCount":97},[],{"trials":4992,"activeCount":97},[],{"trials":4994,"activeCount":97},[],{"intervention":4967,"totalTrials":264,"cells":4996},{"EARLY_PHASE1":4997,"PHASE1":4999,"PHASE2":5005,"PHASE3":5007,"PHASE4":5009,"NA":5011},{"trials":4998,"activeCount":97},[],{"trials":5000,"activeCount":97},[5001],{"nctId":4960,"briefTitle":4961,"status":103,"phases":5002,"primaryCompletion":4630,"completion":4630,"start":1840,"enrollment":503,"conditions":5003,"interventions":5004},[86],[4964],[4953,4966,4967,4968],{"trials":5006,"activeCount":97},[],{"trials":5008,"activeCount":97},[],{"trials":5010,"activeCount":97},[],{"trials":5012,"activeCount":97},[],{"intervention":4968,"totalTrials":264,"cells":5014},{"EARLY_PHASE1":5015,"PHASE1":5017,"PHASE2":5023,"PHASE3":5025,"PHASE4":5027,"NA":5029},{"trials":5016,"activeCount":97},[],{"trials":5018,"activeCount":97},[5019],{"nctId":4960,"briefTitle":4961,"status":103,"phases":5020,"primaryCompletion":4630,"completion":4630,"start":1840,"enrollment":503,"conditions":5021,"interventions":5022},[86],[4964],[4953,4966,4967,4968],{"trials":5024,"activeCount":97},[],{"trials":5026,"activeCount":97},[],{"trials":5028,"activeCount":97},[],{"trials":5030,"activeCount":97},[],{"intervention":5032,"totalTrials":264,"cells":5033},"Encapsulated vortioxetine IR tablet, 20 mg",{"EARLY_PHASE1":5034,"PHASE1":5036,"PHASE2":5048,"PHASE3":5050,"PHASE4":5052,"NA":5054},{"trials":5035,"activeCount":97},[],{"trials":5037,"activeCount":97},[5038],{"nctId":5039,"briefTitle":5040,"status":103,"phases":5041,"primaryCompletion":814,"start":5042,"enrollment":5043,"conditions":5044,"interventions":5046},"NCT02112903","Study Comparing the Gastro-intestinal Tolerability and Absorption Profile of Vortioxetine After Administration of Modified-release Formulations and Immediate-release Formulation in Healthy Women",[86],"2014-04",40,[5045],"Healthy Women",[5032,5047,5047,5047],"Vortioxetine MR capsule 20 mg",{"trials":5049,"activeCount":97},[],{"trials":5051,"activeCount":97},[],{"trials":5053,"activeCount":97},[],{"trials":5055,"activeCount":97},[],{"intervention":5047,"totalTrials":264,"cells":5057},{"EARLY_PHASE1":5058,"PHASE1":5060,"PHASE2":5066,"PHASE3":5068,"PHASE4":5070,"NA":5072},{"trials":5059,"activeCount":97},[],{"trials":5061,"activeCount":97},[5062],{"nctId":5039,"briefTitle":5040,"status":103,"phases":5063,"primaryCompletion":814,"start":5042,"enrollment":5043,"conditions":5064,"interventions":5065},[86],[5045],[5032,5047,5047,5047],{"trials":5067,"activeCount":97},[],{"trials":5069,"activeCount":97},[],{"trials":5071,"activeCount":97},[],{"trials":5073,"activeCount":97},[],{"intervention":533,"totalTrials":264,"cells":5075},{"EARLY_PHASE1":5076,"PHASE1":5078,"PHASE2":5084,"PHASE3":5086,"PHASE4":5088,"NA":5090},{"trials":5077,"activeCount":97},[],{"trials":5079,"activeCount":97},[5080],{"nctId":526,"briefTitle":527,"status":103,"phases":5081,"primaryCompletion":529,"completion":529,"start":444,"enrollment":530,"conditions":5082,"interventions":5083},[86],[32],[51,533],{"trials":5085,"activeCount":97},[],{"trials":5087,"activeCount":97},[],{"trials":5089,"activeCount":97},[],{"trials":5091,"activeCount":97},[],{"intervention":5093,"totalTrials":264,"cells":5094},"[11C]PXT012253",{"EARLY_PHASE1":5095,"PHASE1":5105,"PHASE2":5107,"PHASE3":5109,"PHASE4":5111,"NA":5113},{"trials":5096,"activeCount":97},[5097],{"nctId":5098,"briefTitle":5099,"status":103,"phases":5100,"primaryCompletion":5101,"completion":5101,"start":5102,"enrollment":294,"conditions":5103,"interventions":5104},"NCT03826134","A Positron Emission Tomography (PET) Study to Examine the Brain Binding Properties of a Novel Radioactive Compound [11C]-PXT012253 in Healthy Subjects",[85],"2019-03-15","2019-01-17",[35],[5093],{"trials":5106,"activeCount":97},[],{"trials":5108,"activeCount":97},[],{"trials":5110,"activeCount":97},[],{"trials":5112,"activeCount":97},[],{"trials":5114,"activeCount":97},[],{"intervention":739,"totalTrials":1073,"cells":5116},{"EARLY_PHASE1":5117,"PHASE1":5119,"PHASE2":5129,"PHASE3":5159,"PHASE4":5239,"NA":5283},{"trials":5118,"activeCount":97},[],{"trials":5120,"activeCount":97},[5121],{"nctId":5122,"briefTitle":5123,"status":103,"phases":5124,"primaryCompletion":1282,"start":5125,"enrollment":696,"conditions":5126,"interventions":5128},"NCT01607125","Exploratory Study of the Effects of Vortioxetine (Lu AA21004) on Cognition and Blood Oxygen Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signals in Subjects Remitted From Depression and in Controls",[86],"2012-07",[5127],"Depression",[739],{"trials":5130,"activeCount":97},[5131,5138,5146,5155],{"nctId":5132,"briefTitle":5133,"status":103,"phases":5134,"primaryCompletion":1313,"completion":1876,"start":5135,"enrollment":485,"conditions":5136,"interventions":5137},"NCT00761306","Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults",[87],"2007-06",[18],[739],{"nctId":5139,"briefTitle":5140,"status":103,"phases":5141,"primaryCompletion":5142,"completion":5142,"start":5143,"enrollment":1247,"conditions":5144,"interventions":5145},"NCT02919501","Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg\u002FDay Vortioxetine Orally in Patients With Major Depressive Disorder",[87],"2017-04-27","2016-09-27",[1629],[739,739],{"nctId":5147,"briefTitle":5148,"status":103,"phases":5149,"primaryCompletion":1225,"completion":3815,"start":1724,"enrollment":5150,"conditions":5151,"interventions":5154},"NCT01491035","Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder",[87],48,[5152,5153],"Depressive Disorder","Anxiety Disorder",[739,739,739,739],{"nctId":2873,"briefTitle":2874,"status":103,"phases":5156,"primaryCompletion":2876,"completion":2877,"start":2878,"enrollment":2879,"conditions":5157,"interventions":5158},[87],[18],[739,2864],{"trials":5160,"activeCount":97},[5161,5168,5172,5179,5189,5193,5201,5205,5214,5222,5226,5230],{"nctId":5162,"briefTitle":5163,"status":103,"phases":5164,"primaryCompletion":685,"completion":598,"start":656,"enrollment":5165,"conditions":5166,"interventions":5167},"NCT00694304","Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults",[88],535,[18],[739],{"nctId":733,"briefTitle":734,"status":103,"phases":5169,"primaryCompletion":611,"completion":611,"start":674,"enrollment":736,"conditions":5170,"interventions":5171},[88],[18],[739,739,739,711],{"nctId":5173,"briefTitle":5174,"status":103,"phases":5175,"primaryCompletion":5176,"start":1810,"enrollment":796,"conditions":5177,"interventions":5178},"NCT01422213","Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder",[88],"2013-05",[18],[739,739],{"nctId":5180,"briefTitle":5181,"status":252,"phases":5182,"primaryCompletion":5183,"completion":5184,"start":5185,"enrollment":5186,"conditions":5187,"interventions":5188},"NCT02871297","Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age",[88],"2022-03-25","2022-04-19","2016-08-17",662,[1629],[739],{"nctId":1690,"briefTitle":1691,"status":103,"phases":5190,"primaryCompletion":1246,"start":1693,"enrollment":1694,"conditions":5191,"interventions":5192},[88],[18],[739,1671],{"nctId":5194,"briefTitle":5195,"status":103,"phases":5196,"primaryCompletion":5197,"completion":1410,"start":803,"enrollment":5198,"conditions":5199,"interventions":5200},"NCT01323478","Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults",[88],"2012-09",71,[18],[739],{"nctId":741,"briefTitle":742,"status":103,"phases":5202,"primaryCompletion":744,"start":745,"enrollment":746,"conditions":5203,"interventions":5204},[88],[18],[739,711],{"nctId":5206,"briefTitle":5207,"status":103,"phases":5208,"primaryCompletion":5209,"completion":5209,"start":5210,"enrollment":5211,"conditions":5212,"interventions":5213},"NCT03108625","Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age",[88],"2020-04-16","2017-03-01",94,[1629],[739],{"nctId":5215,"briefTitle":5216,"status":252,"phases":5217,"primaryCompletion":4568,"completion":5218,"start":5219,"enrollment":1683,"conditions":5220,"interventions":5221},"NCT05014919","Vortioxetine to Prevent Return of Symptoms in Children With Depression",[88],"2022-04-28","2021-08-10",[5127],[739],{"nctId":2266,"briefTitle":2267,"status":103,"phases":5223,"primaryCompletion":2269,"start":2270,"enrollment":2271,"conditions":5224,"interventions":5225},[88],[18],[739,2255],{"nctId":750,"briefTitle":751,"status":103,"phases":5227,"primaryCompletion":753,"completion":685,"start":631,"enrollment":754,"conditions":5228,"interventions":5229},[88],[18],[739,711],{"nctId":5231,"briefTitle":5232,"status":103,"phases":5233,"primaryCompletion":5234,"completion":1311,"start":5235,"enrollment":5236,"conditions":5237,"interventions":5238},"NCT00596817","Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes",[88],"2009-09","2007-12",639,[18],[739],{"trials":5240,"activeCount":97},[5241,5251,5262,5272,5279],{"nctId":5242,"briefTitle":5243,"status":103,"phases":5244,"primaryCompletion":5245,"completion":5246,"start":5247,"enrollment":9,"conditions":5248,"interventions":5250},"NCT04294654","Vortioxetine in Patients With Depression and Early Dementia",[89],"2022-07-06","2022-07-20","2020-02-28",[18,5249],"Dementia",[739],{"nctId":5252,"briefTitle":5253,"status":103,"phases":5254,"primaryCompletion":5255,"completion":5255,"start":5256,"enrollment":5257,"conditions":5258,"interventions":5261},"NCT04220996","Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD)",[89],"2021-03-09","2019-12-27",100,[5259,5260],"MDD","Anxiety Disorders",[739],{"nctId":5263,"briefTitle":5264,"status":103,"phases":5265,"primaryCompletion":5266,"completion":5267,"start":5268,"enrollment":5269,"conditions":5270,"interventions":5271},"NCT04288895","Open-label, Flexible-dose Study of Vortioxetine in Patients With Depression in India",[89],"2022-02-11","2022-03-12","2020-02-20",400,[18],[739],{"nctId":5273,"briefTitle":5274,"status":103,"phases":5275,"primaryCompletion":5276,"completion":5276,"start":1110,"enrollment":364,"conditions":5277,"interventions":5278},"NCT03835715","Study With Vortioxetine on Emotional Functioning in Patients With Depression",[89],"2020-02-21",[18],[739],{"nctId":995,"briefTitle":996,"status":103,"phases":5280,"primaryCompletion":998,"completion":999,"start":1000,"enrollment":1001,"conditions":5281,"interventions":5282},[89],[18],[739,982],{"trials":5284,"activeCount":97},[5285],{"nctId":5286,"briefTitle":5287,"status":103,"phases":5288,"primaryCompletion":5289,"completion":5289,"start":5290,"enrollment":5291,"conditions":5292,"interventions":5293},"NCT03555136","Real-life Effectiveness of Vortioxetine in Depression",[],"2021-01-31","2017-11-17",992,[18],[739]]